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Abstract 
The absence of pain management for common husbandry procedures, such as dehorning 
and castration of cattle, is considered to be an important animal welfare consideration, but there 
are currently no drugs approved by the FDA for the purpose of providing pain relief in cattle.  
The FDA’s Center for Veterinary Medicine (CVM) recognizes the need for the availability of 
pain-relieving drugs and has encouraged research into the development of behavioral and 
physiologic measures which can reliably demonstrate the effectiveness in that species.  The 
USDA has also recognized this need by providing grants for research into investigating pain 
models for cattle that can be used for the development of pain mitigation methods.  The studies 
reported in this dissertation were funded by the USDA and the American Association of Bovine 
Practitioners.  They add to the body of knowledge from which a pain model in cattle may 
eventually be validated for use in the drug approval process and also contribute to knowledge 
base for a candidate non-steroidal anti-inflammatory drug for convenient use in cattle.  
The study reported in Chapter 2 was conducted to support research of a candidate pain-
assessment variable, substance P.  This study provides future researchers with recommended 
sample handling procedures for obtaining reliable and repeatable results, which is important if 
substance P is to be validated as pain biomarker in cattle.  The study in Chapter 3 investigated 
the  use of several variables for use in a pain model.  The results provided researchers, 
veterinarians and policy-makers with evidence to support the common practice of castrating and 
dehorning calves at the same time rather than as individual procedures separated by a healing 
interim.  The study in Chapter 4 investigated the pharmacokinetics of oral meloxicam when 
administered to juvenile ruminant and pre-ruminant calves.  This study added to the growing 
knowledge base of the pharmacokinetics of oral meloxicam in cattle and also provided 
practitioners with practical information concerning the administration of the drug in milk 
replacer.  Chapter 5 investigated the use of oral meloxicam in a production setting and indicated 
that meloxicam administration prior to surgical castration may reduce the incidence of 
respiratory disease in the post-surgical period.
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Abstract 
The absence of pain management for common husbandry procedures, such as dehorning 
and castration of cattle, is considered to be an important animal welfare consideration, but there 
are currently no drugs approved by the FDA for the purpose of providing pain relief in cattle.  
The FDA’s Center for Veterinary Medicine (CVM) recognizes the need for the availability of 
pain-relieving drugs and has encouraged research into the development of behavioral and 
physiologic measures which can reliably demonstrate the effectiveness in that species.  The 
USDA has also recognized this need by providing grants for research into investigating pain 
models for cattle that can be used for the development of pain mitigation methods.  The studies 
reported in this dissertation were funded by the USDA and the American Association of Bovine 
Practitioners.  They add to the body of knowledge from which a pain model in cattle may 
eventually be validated for use in the drug approval process and also contribute to knowledge 
base for a candidate non-steroidal anti-inflammatory drug for convenient use in cattle.  
The study reported in Chapter 2 was conducted to support research of a candidate pain-
assessment variable, substance P.  This study provides future researchers with recommended 
sample handling procedures for obtaining reliable and repeatable results, which is important if 
substance P is to be validated as pain biomarker in cattle.  The study in Chapter 3 investigated 
the  use of several variables for use in a pain model.  The results provided researchers, 
veterinarians and policy-makers with evidence to support the common practice of castrating and 
dehorning calves at the same time rather than as individual procedures separated by a healing 
interim.  The study in Chapter 4 investigated the pharmacokinetics of oral meloxicam when 
administered to juvenile ruminant and pre-ruminant calves.  This study added to the growing 
knowledge base of the pharmacokinetics of oral meloxicam in cattle and also provided 
practitioners with practical information concerning the administration of the drug in milk 
replacer.  Chapter 5 investigated the use of oral meloxicam in a production setting and indicated 
that meloxicam administration prior to surgical castration may reduce the incidence of 
respiratory disease in the post-surgical period.
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Chapter 1 - Literature Review 
 
 Introduction 
The absence of pain management for common surgical procedures, such as dehorning 
and castration of cattle, is considered to be an important animal welfare concern and has been 
under consideration in the development of international trade agreements (Phillips, 2008; 
Thiermann & Babcock, 2005).   There are currently no drugs approved by the U.S. Food and 
Drug Administration (FDA) for the express purpose of providing pain relief in cattle.  Lidocaine, 
is approved for the administration of short-acting local anesthesia.  Flunixin meglumine, a non-
steroidal anti-inflammatory drug, is approved for controlling pyrexia and inflammation in cattle 
with intravenous administration. The FDA’s Center for Veterinary Medicine (CVM) recognizes 
the need for the availability of pain-relieving drugs, and with the aim of improving the 
availability of drugs to control pain in cattle, the CVM  is currently encouraging research into the 
development of behavioral and physiologic measures which can reliably demonstrate the 
effectiveness in that species (Smith, 2013).   
The research for this dissertation was conducted to investigate measures which may be 
used for the development of pain-mitigation strategies, when performing castration and 
dehorning of cattle.  Furthermore, this research was conducted to further the understanding of the 
pharmacokinetics of an analgesic drug, meloxicam, in cattle and to investigate its use as a 
candidate for providing analgesia in cattle when subjected to castration. 
 Overview of animal husbandry procedures in modern livestock production settings 
The castration and dehorning of cattle are common husbandry procedures which, in 
modern society and production agriculture, convey benefits to producers, consumers, and to the 
animals themselves. Although the procedures inflict pain and are associated with a post-
procedure period of reduced feed efficiency and reduced growth rate, the benefits are considered 
to outweigh the negative aspects. Castration of bulls has long been practiced to produce steers 
which are less aggressive to man and to each other.  Additionally, castration prevents unwanted 
matings with co-mingled females and produces carcass traits which are desirable to consumers 
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(AVMA, 2011a).  Horns on cattle increase the risk of injury to man and animals alike.  Cattle 
with horns may injure each other while eating at the feed bunk, during aggressive displays of 
dominance, and during close confinement and transportation.  The carcasses of dehorned cattle 
tend to have less wastage due to bruising (AVMA, 2011b).  
Cattle destined to be dehorned and/or castrated are derived from two distinct cattle 
production systems: beef and dairy.  The different handling processes and the different genetics 
within those industries affect when the dehorning and castration procedures occur.  In the dairy 
industry, calves are usually separated from the dam within 24 h after parturition and raised by 
producers with the provision of milk-replacer and a target weaning date of approximately 6 to 8 
weeks of age. Whether calves are retained on the farm, sent to a heifer-raising facility, or sold to 
another producer for entry into the veal or finished beef channels, the animals are handled from 
birth and there is opportunity to perform husbandry procedures at a young age.  Most dairy 
calves require dehorning since the horned Holstein breed comprises 90% of all dairy cows in the 
U.S. (USDA, 2007a). In a USDA survey of dairy farm practices, the majority of heifer calves 
were disbudded by hot iron (68%) or caustic paste (12%) before 8 weeks of age which is 
approximately when the horn bud begins to attach to the frontal bone.  Tube, spoon, or gouge 
tools were used at a mean age of 17 weeks in 12% of heifer calves, and saws, wires, or Barnes 
dehorners were used on the remaining 8% of heifers at an average age of 24 weeks.  Analgesics 
or anesthesia were used in 18% of operations. A survey of north central and northeastern dairies 
reported a similar method and age structure for dehorning calves, but reported lower percentages 
of operations using anesthetics (12.4%) and analgesics (1.8%) (Fulwider et al., 2008).  When 
retained on the dairy farm, most calves were castrated at an average age of 9 weeks with either 
band (61%), knife (27%), or burdizzo (12%).  Analgesics or anesthesia were used routinely for 
castration in 3.2% of operations. (USDA, 2007a).  Information from producers concerning the 
timing of castration and dehorning of bull calves not retained on a dairy farm is not readily 
available, but in a survey of veterinarians in bovine practice, more respondents reported 
castrating greater numbers of dairy calves weighing between 90 – 270 kg, than those weighing 
more than 270 kg (Coetzee, et al., 2010). 
In the beef industry, calves generally remain with the dam in a pasture environment until 
weaning at approximately 6 to 10 months of age.  Although some beef calves may be dehorned 
and castrated prior to weaning, many calves are not handled until removed from the dam.  In 
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some operations, prior to marketing, calves undergo a post-weaning backgrounding period, in 
which they are vaccinated, castrated, dehorned, and acclimated to feeding from a bunk. In a 
USDA survey of beef cow-calf operations, approximately 80% of bull calves were castrated 
prior to sale in 2007-08 (USDA. 2008a).  The remaining 20% of calves would not be castrated 
until after going through the stresses of the marketing process and the transported to a stocker 
operation or feeding facility. Due to a higher percentage of polled genetics in beef breeds, fewer 
calves require dehorning than dairy breeds. In a USDA survey of beef cow-calf operations, the 
percent of beef calves born with horns decreased from 28% in 1997 to 12% in 2007.  Horned 
calves were dehorned at an average age of 120 days, with 43% of calves being dehorned by 3 
months of age, but with 25% not being dehorned until after 6 months of age (USDA, 2008a).    
The USDA study did not report beef producers’ use of anesthetics or analgesics in 
castration and dehorning procedures.  Two recent surveys of bovine practitioners, however, 
allow some insight into the provision of pain relief when a veterinarian is called upon to perform 
routine husbandry procedures.  Coetzee, et al (2010) reported that most producers castrated 
calves themselves in the perinatal period when animals weighed under 90 kg, but hired a 
veterinarian to perform castrations of calves over 270 kg, which is the approximate weaning 
weight of beef breeds.  Between 90 and 270 kg, producers and veterinarians performed the 
castrations in nearly equal proportions. The survey does not indicate whether veterinarians used 
surgical or non-surgical methods more in one weight group than another, but does indicate that a 
scalpel method is used most often in surgical castration and that elastic bands or rings are most 
commonly used in non-surgical castration.  The survey also reported that 20% of veterinarians 
used analgesia or anesthesia at the time of castration, and when dehorning was necessary, 90% of 
veterinarians performed dehorning and castration concurrently. Another survey (Fajt et al., 2011) 
of bovine practitioners reported that 30% of veterinarians provided anesthesia or analgesia to 
calves under 6 months of age when castrating, but 45% provided local anesthesia and/or an 
alpha-2 adrenergic agonist to calves 6 months of age or older.  When dehorning calves at either < 
6 mo-old or > 6 mo-old, a smaller percentage of veterinarians provided anesthesia or analgesia to 
beef calves (49% and 64%) than to dairy calves (63% and 73%).  Although Fajt et al. (2011) did 
not speculate on the reason for the lower percentages associated with beef calves, one reason 
may be that the administration of medication slows the rate of processing. Commonly cited 
reasons why analgesia is not provided to cattle when undergoing castration and dehorning 
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include practical and economic factors, scarcity of analgesic agents licensed for use in cattle, 
difficult in administration and concern of drug residues in food tissues. (Vinuela-Fernandez et 
al., 2007). 
It is important to note that veterinarians in the U.S. are hampered in the provision of 
analgesia to food animals because no drugs have been approved by the FDA for the treatment of 
pain in those species.  The only analgesic drug licensed for use in food animals in the U.S. is 
flunixin meglumine, and its labeled use is for the control of pyrexia associated with bovine 
respiratory disease and for the control of inflammation and pyrexia associated with endotoxemia 
(FDA, 2003). However, due in part to increased societal concern over animal welfare issues in 
the popular press, there has been increased public scrutiny of the use (or non-use) of analgesia 
and anesthesia in routine husbandry procedures of cattle and other farm livestock (Martin, 2008; 
McKinley, J. 2010).  In the U.S., the performance of these routine surgeries in livestock, without 
the benefit of pain-reducing techniques, has been exempt from state cruelty laws because it has 
been a widespread practice.  There is indication, however, that this may change.  The New Jersey 
Supreme court has declared that castration without alleviation of pain cannot be considered 
humane just because the practice is widespread.  Pressure to change the status quo concerning 
the lack of pain-mitigating standards in the U.S. comes not only from internal sources, but 
external as well.  The absence of pain management for common surgical procedures is 
considered to be an important animal welfare concern and is under consideration in the 
development of international trade agreements (Phillips, 2008; Thiermann & Babcock, 2005).  It 
is understandable that countries which regulate how and when animal husbandry procedures are 
performed within their own borders feel that trading partners should follow similar standards, 
both for economic and ethical reasons.  Whether from domestic or foreign pressure, officials in 
the U.S. have been, or are being, charged with revising legislation governing the humane 
treatment of food-producing animals (Cowan, 2011).   
In order for these new standards to actually increase the well-being of animals, it is 
necessary that they be based upon solid scientific basis.  To assist the formulation of regulations 
concerning castration and dehorning of cattle, the scientific literature must contain reproducible 
studies which investigate the effects of animal age and procedure method upon the animals’ 
response.  Measuring pain in animals difficult because they cannot describe the subjective 
amount of pain they feel in terms which humans can readily understand and quantify.  Therefore, 
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we attempt to measure the amount of pain which an animal experiences due to a specific 
procedure through changes which occur in the animals’ behavior and physiology.  We gauge the 
effectiveness of a specific pain-mitigating strategy by the absence, or lessening, of those 
behavioral and physiological changes when the procedure is performed with the provision of that 
strategy. 
 
Response variables in bovine pain research   
The potential response variables with which pain may be estimated are derived from the 
animal’s responses which can be measured.  Physiologic variables which have been measured in 
association with pain in cattle include heart rate (Schwartzkopf-Genswein et al.,2005; Stewart et 
al., 2008, 2010), heart rate variability (Stewart et al., 2008, 2010), external temperature of skin or 
membranes (Stewart et al., 2008, 2010); brain waves (Bergamasco et al., 2011), electrodermal 
activity (Kotschwar et al., 2009; Baldridge et al., 2011) and circulating concentrations of 
biological molecules such as cortisol (Stafford and Mellor, 2005), epinephrine and 
norepinephrine (Stewart et al., 2010), substance-P (Coetzee et al., 2008), interferon-γ, and acute 
phase proteins (Early and Crowe, 2002).   Changes in behavior have been used as summary 
measures of the animal’s overall response as it attempts to maintain homeostasis in response to 
external threats and internal changes.  Variables associated with behavior changes which have 
been utilized include vocalization during the procedure (Schwartzkopf-Gentzwein et al., 2005), 
velocity with which the animal leaves the area where the procedure occurred (Baldridge et al., 
2011), behavioral count measures such as the number of kicks, ear flicks, tail flicks, scratching, 
or turning to look at the area, and behavior duration measures such as the amount of time spent 
standing, lying, eating, drinking, and specific postures (Millman, 2013).  Performance variables 
such as weight gain, dry matter intake, and the incidence of succumbing to infectious disease 
have an underlying basis in physiology and behavior, are useful as summary indicators of an 
animal’s overall wellbeing, and are important to producers (Fisher et al., 1996; Baldridge et al., 
2011; Massey et al., 2011).     
The physiological variables measured in pain studies are not necessarily specific to 
nociception, but may change in response to the stress of a perceived threat as well or due to 
inflammation.  Perceived or actual threat to the body is met with activation of two intertwined 
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stress-axes: the sympatho-adrenal (SA) and the hypothalamic-pituitary-adrenal (HPA) axes. The 
signal of an actual threat to the body is transmitted to the brain by nociceptive neural impulses 
from the site of tissue stimulation or damage.   
The adrenal glands play a crucial role in both SA and HPA axes, with the secreted 
catecholamines and glucocorticoids forming an immediate “fight-or-flight” reaction and a slower 
adaptive response which functions to return the body to normal homeostatic conditions.  In the 
SA axis, neural transmission causes a response from the adrenal medulla to occur within 
milliseconds, whereas activation of the adrenals via the HPA axis is slower, requiring a chain of 
events to occur via the bloodstream.  In the HPA axis, following stimulation, the hypothalamus 
releases corticotrophin-releasing hormone (CRH), which then stimulates the anterior pituitary to 
release adreno-corticotropic hormone (ACTH), which in turn stimulates the cells in the adrenal 
cortex to release glucocorticoids, such as cortisol, into the bloodstream.  The activity of the HPA 
axis is excited by catecholamines and suppressed by cortisol in a negative-feedback mechanism 
which limits its own production.  Cortisol also functions to limit the biosynthesis and release of 
epinephrine from the adrenal gland to dampen the state of excitation.  (Axelrod & Reisine, 1994; 
Ehrhart-Bornstein, 2998) 
Catecholamines are quickly cleaved enzymatically, with a plasma half-life of 1 to 2 
minutes (Hjemdahl, 1993), which presents logistical difficulty in collecting, preserving, and 
assaying samples that are representative of the biological state at the time of a procedure.  
Therefore, alternative methods have been investigated to approximate the level of arousal of the 
SA axis.  The effects of catecholamine release in the body are supportive of the rapid fight-or-
flight response by promoting energy mobilization, diverting blood supply from skin and internal 
organs toward the muscles, and increasing respiration, as well as cardiac output.  Thus, response 
variables which are intended to approximate the level of SA axis activation include respiratory 
rate, electrodermal conductivity, heart rate, and heart rate variability.  Cortisol has been utilized 
extensively in the literature as a measure of the stress associated with a procedure, with the 
notion that more painful procedures are more stressful to the animal.  The value of cortisol as a 
biomarker for the approximation of pain is limited because its circulating concentration may be 
influenced by perceived threats as well as actual threats.  Furthermore, cortisol levels are 
regulated by a negative feedback mechanism which creates a ceiling effect whereby increased 
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pain may not result in increased cortisol concentration within the body (Axelrod and Reisine, 
1984).  
Numerous studies have investigated the various abovementioned response variables in 
the single procedure of either castration (Stafford and Mellor, 2005) or dehorning (Stafford and 
Mellor, 2004).  However, studies are scarce which have compared the relative noxiousness of 
castration to dehorning or to a procedure in which castration and dehorning are performed 
concurrently, yet in a survey of U.S. veterinarians in bovine practice, 90% of respondents 
indicated that they dehorn calves at the same time as castration (Coetzee et al., 2010).  One study 
has investigated separate castration and dehorning procedures in the same calves, but the 
procedures were performed in series, with castration always following dehorning, so 
comparisons between procedures were confounded with order of application (Schwartzkopf-
Genswein, et al., 2005). Another study has investigated castration, dehorning, and the concurrent 
procedure, in parallel but not in series (Ballou et al., 2013; Sutherland et al., 2013.)  Therefore, 
Chapter 3 of this dissertation investigates the utility of a number of these variables in a study 
involving castration, dehorning, and concurrent dehorning and castration in sequence and in 
parallel. 
Substance P has recently come under investigation as a biomarker which may be more 
specific to the pain response than substances produced in the SA or HPA axes (Coetzee et al., 
2008, 2012; Sutherland et al., 2012; Glynn et al., 2013; Dockweiler et al., 2013, Allen et al. 
2013.).  A member of the tachykinin family, substance P is known classically as a neuropeptide 
which is produced and released at both the central and peripheral terminals of bi-polar 
peptidergic C fibers which, in concert with the primary neurotransmitter glutamate, transmits the 
message of nociception (Otsuka and Yoshioka, 1993).  Substance P is also produced in adrenal 
chromaffin cells, and co-stored with other neuropeptides and adrenomedullary catecholamines 
(Ehrhart-Bornstein et al., 1998).  Substance P production and activity is not, however, specific to 
neurologic tissue.  Substance P also plays a role in the inflammatory process by causing 
vasodilation, microvascular leakage, and the attraction and activation of cells with 
immunological function.  The molecule has been shown to be produced by non-neural 
mammalian cells including vascular endothelium, monocytes, macrophages, eosinophils and 
tissues associated with the respiratory, gastrointestinal and genito-urinary tracts (Linnik and 
Moskowitz, 1989; Ho et al.,1997; Lecci and Maggi, 2001; Pinto et al., 2004).   Since the use of 
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Substance P is relatively novel as a biomarker of pain in cattle, more research is necessary to 
validate its use, and to provide researchers with methodological information such as best 
practices for collecting and handling samples destined for analysis of SP.  Chapter 2 of this 
dissertation investigates the effects on SP in bovine blood of various protease inhibitors, the 
length of time samples were held prior to the harvesting of plasma, and the temperature at which 
samples were held. 
 
NSAIDs in dehorning and castration research 
Non-steroidal anti-inflammatory drugs which have been investigated in either dehorning 
or castration studies include flunixin meglumine (Stillwell, 2008; Gonzalez et al., 2010; Webster, 
2010), ketoprofen (Earley & Crowe, 2002; Ting et al., 2003a, 2003b), salicylic acid (Coetzee et 
al., 2007; Baldridge et al., 2011), carprofen (Pang et al., 2006; Stillwell, 2008), and recently, oral 
meloxicam (Glynn et al., 2013).  
The rationale for the use of NSAIDs, and meloxicam in particular, is discussed in depth 
in Chapters 4 and 5. 
 NSAIDs in bovine respiratory disease research 
In the beef cattle industry at weaning time, calves generally undergo a period of extreme 
stress in which they are weaned from their dams, transported for various distances, commingled 
with other calves at either the livestock market or feedlot facility, and undergo a change in 
feeding practice.  The immune system is negatively affected by such stressors, which makes the 
animal more susceptible to contracting infectious agents and succumbing to disease.  Bovine 
respiratory disease (BRD), with multiple causative bacterial and viral organisms, is the most 
common cause of illness and death in feedlot calves, with the highest incidence of disease 
occurring within 28 days of arrival at the feedyard (Buhman et al., 2000; Duff and Galyean, 
2007).  
 Bull calves may be castrated before weaning, but many are not castrated until reaching 
the feedlot, further stressing the animal.  The surgical castration of cattle is generally followed by 
a period of decreased animal performance as evidenced by reduced average daily gain (ADG), 
daily feed intake (DFI), and gain-to-feed ratio (ADG:DFI), (Faulkner et al., 1992; Bretschneider, 
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2005; Stafford and Mellor, 2005; AVMA, 2011; Massey et al., 2011).  Furthermore, surgical 
castration is associated with increased levels of cortisol and acute phase proteins such as 
haptoglobin, with ensuing immune suppression which may increase the likelihood of the animal 
succumbing to disease. (Fisher et al., 1997; Earley and Crowe, 2002).    
 In a study in which an inflammatory response was induced in calves by intravenously 
injecting the endotoxin of Escherichia coli, LPS, a single administration of meloxicam was 
shown to stimulate synthesis of leukotriene B4 compared to controls. (Bednarek & Kondracki, 
2006).  This stimulation indicates a positive immune reaction because leukotriene B4 is an 
immune cell chemoattractant and is thought to activate macrophages for enhanced phagocytosis 
and to activate neutrophils for enhanced killing of pathogens (Bednarek & Kondracki, 2006; Yoo 
et al., 1995.)  In a later study, in calves suffering from BRD, the NSAID flunixin meglumine was 
administered as an adjunctive therapy to antimicrobial treatment.  Calves treated with the NSAID 
showed a faster clinical recovery from BRD and blood samples showed increased numbers of 
lymphocytes and their subpopulations (CD2(+), CD4(+), CD8(+), WC4(+) cells) than calves not 
receiving the NSAID (Bednarek et al., 2013).   
 In a model of induced bovine respiratory disease, carprofen has also been shown to 
reduce the clinical disease scores and the extent of pulmonary lesions in cattle (Wallemacq et al., 
2007). 
 In the study reported in Chapter 6, the results of administering meloxicam to newly-
received calves prior to castration at the feedlot are reported.   
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Chapter 2 - Effects of sample handling methods on substance P 
concentrations and substance P immunoreactivity in bovine blood1 
  
 Introduction 
  
Due to societal concern for the welfare of farm animals, numerous organizations have 
implemented or are considering the implementation of regulations concerning painful husbandry 
procedures such as dehorning and castration.1  In order to provide proper scientific evidence for 
regulatory decisions and for the development of pain-mitigating options, there is need for studies 
which investigate pain-relieving techniques in food animal species.  A major impediment in 
drawing conclusions from these studies is the absence of an objective measure of pain in 
animals.  Cortisol has been used as a response variable to approximate the relative noxiousness 
of a procedure in numerous studies, but its limitations have also been recognized.2  Substance P 
has been investigated as a response variable which may be more specific to pain experienced by 
an animal.3-10  In support of research which may utilize SP as a response variable, this study 
investigated the effects of various sample handling techniques on the recovery of SP in blood 
samples when analyzed by ELISA or LC-MS/MS methodology. 
Substance P is a biologically active peptide, long known to play a role in the neural 
transmission of nociceptive signals from sites of peripheral insult to the central nervous system.11  
Substance P is released by peptidergic peripheral sensory nerve fibers at both, the central 
synaptic junctions in the dorsal horn of the spinal cord and at the peripheral terminals, where the 
peptide plays a signaling role in the transmission of pain as well as the induction of inflammation 
and central sensitization.12   
Substance P is a member of the tachykinin family and is synthesized in cell bodies from 
transcripts of the gene, Preprotachykinin-A.  The parent SP peptide is composed of 11 amino 
                                                 
1 Reprinted with permission from " Chapter 2 - Effects of sample handling methods on substance P concentrations 
and substance P immunoreactivity in bovine blood " by Ruby A. Mosher, DVM; Johann F. Coetzee, BVSc, PhD; 
Portia S. Allen, MS; James Havel, B.S.; Gary R. Griffith, PhD; Chong Wang, PhD. Accepted for publication Sept 
2013.  American Journal of Veterinary Research.  American Veterinary Medical Association. 
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acids with an amidated carboxyl terminus (Arg1-Pro2-Lys3-Pro4-Gln5-Gln6-Phe7-Phe8-Gly9-
Leu10-Met11-NH2) and will be specifically identified from here on as SP1-11.  The various 
enzymes which may cleave SP1-11 include members of the serine- and metallo-protease families: 
angiotensin I converting enzyme, aminopeptidase, neutral endopeptidase, dipeptidyl peptidase 
IV, and post-proline cleaving enzyme.13,14   Enzymes of the different classes require inhibitors 
with specific affinity for their catalytic site, thus the protection of SP1-11 from enzymatic 
degradation may require the addition of at least two inhibitor types. Various degradation 
products are derived from SP1-11, and are named according to the fragment of amino acids 
contained.  For example, the cleavage of SP1-11 between the Pro2 and Lys3 results in the 
formation of two fragments, SP1-2, and SP3-11.   Fragments containing at least the five C-terminal 
amino acids, i.e. fragments from SP1-11 to SP7-11, elicit similar biological effects as the parent SP 
peptide, though potency decreases with fewer amino acids.15  Opposite effects have been 
demonstrated between fragments containing either the hydrophobic C-terminal or the hydrophilic 
N-terminal, with a recent study suggesting that the antinociceptive effects of morphine were 
enhanced when combined with SP1-7.16   Knowledge of the fragmentation profile of substance P 
may therefore increase our understanding of pain processing and perception in animals.   
   Concentrations of SP can be measured by ELISA or LC-MS/MS methodology.  Whereas 
LC-MS/MS has the ability to measure concentrations of SP1-11 specifically, the ELISA assay 
provides a summary measure of SP immunoreactivity which includes not only SP1-11, but 
C-terminal fragments and other related immunoreactive peptides as well. One commercially 
available ELISA testa indicates cross reactivities between the assay and metabolites as: SP1-11 
(100%), SP3-11 (87.9%), SP4-11 (11.7%), and SP7-11 (5.9%).  From here on this summary measure 
will be identified as SPELISA.   
In studies involving livestock, sample-handling conditions are not always ideal.  With 
barns often being distant from laboratory facilities, refrigeration or ice may not be available for 
chilling samples.  Furthermore samples may be held in batches for transport to the laboratory 
where delayed processing occurs.  Therefore, in support of research which utilizes the assay of 
SP as a response variable, we wanted to compare the effects of certain handling procedures upon 
the concentrations of SP1-11, SP3-11, and SP7-11 measured by LC-MS/MS and upon levels of 
SPELISA immunoreactivity as measured by ELISA.  In this exploratory study, we investigated the 
effects of delayed blood sample processing (up to 24 h) and the temperature (ice bath or ambient) 
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at which the sample was held during that period.  With respect to the ability to protect SP1-11 and 
SPELISA from degradation, we compared the enzyme inhibitor aprotinin, 500 KIU/ml in EDTA, 
as recommended by the ELISA kita used in the study, with a lower concentration of 50 KIU/ml.  
We also evaluated whether a commercially-marketed complete protease inhibitor cocktail may  
be more effective at preventing the decay of SP than aprotinin, and whether those treatments are 
more effective than simply collecting blood in readily available EDTA or heparin tubes.    
 Materials and Methods 
All experimental procedures in this study were approved by the Kansas State University 
Institutional Animal Care and Use Committee under the supervision of the University 
Veterinarian.  An overview of the study is provided in Figure 1. 
Collection Tube Preparation   
Enzyme inhibitor treatments were prepared and added to blood collection tubes 
approximately eight hours prior to the study commencement.  Aprotinin powder was dissolved 
and serially diluted with deionized water to create two stock solutions that would provide final 
concentrations of 50 KIU/ml and 500 KIU/ml when diluted in the collected blood sample.   A 
commercially available protease inhibitor cocktail tabletb was dissolved and serially diluted in 
deionized water according to manufacturer’s recommendations to provide solutions of single-
strength and double-strength when diluted in the blood sample.  To prepare tubes containing one 
of the levels of aprotinin or complete protease inhibitor cocktail, 100 µL of a concentrated stock 
solution was added to an uncapped 4 mL K3EDTA blood collection tube.  All tubes were 
recapped and refrigerated overnight.   
 Approximately 1 h prior to the blood collection, a spiking solution of SP1-11 was prepared 
by adding 1 mL of 0.1% formic acid to a vial containing 425,000 ng SP1-11.  From this solution, 
serial dilutions were made with 0.1% formic acid to obtain a solution containing 50 ng/mL 
SP1-11.  Fifty microliters of the SP1-11 solution were added to each of the prepared enzyme 
inhibitor tubes, as well as tubes containing lithium heparin or only K3EDTA, to provide a final 
concentration of 625 pg/mL when mixed with 4 mL of whole blood. 
 The blood tubes were arranged in 3 replicate arrays for each holding period. The arrays 
destined for holding periods of 1, 3, 6, 12, and 24 h, each contained two sets (one for each 
temperature treatment) of the following 6 enzyme inhibitor treatments spiked with 625 pg/ml 
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SP1-11:  1) heparin, 15 USP/ml (HEP); 2) EDTA, 1.8 mg/mL (EDTA); 3) aprotinin, 50 KIU/ml in 
EDTA (AP50); 4) aprotinin 500 KIU/ml in EDTA (AP500); 5) single-strength protease inhibitor 
tablet in EDTA (TAB1X); and 6) double-strength complete protease inhibitor tablet in EDTA 
(TAB2X).  Arrays destined for immediate processing contained only one set of the 6 inhibitor 
treatments because there was no temperature treatment.  In addition to the treatment tubes, each 
array also contained one non-spiked TAB2X tube that would be processed immediately to detect 
levels of endogenous SP.  In collecting the non-spiked samples in the TAB2X inhibitor, it was 
assumed a priori, that this inhibitor cocktail might provide the fullest extent of protection against 
the different types of enzymes which degrade SP.  All tubes were then held in a coolers filled 
with crushed ice for transport to the barn facility where the blood collection procedure occurred. 
 
Blood Collection Procedure  
Whole blood was obtained from a healthy 6-mo-old Holstein calf.  Approximately 18 
hours prior to the study, the calf was restrained in a chute while an indwelling jugular catheter 
was surgically placed using local anesthesia. To maintain patency, the catheter was flushed with 
a heparin solution.  
 On the morning of the study, the calf was again restrained in the chute while the tubes in 
three arrays were uncapped in preparation for filling from the first blood collection series.   The 
heparin solution was cleared from the catheter by attaching a syringe, and in three repetitions, 
drawing 5 ml blood into the syringe, then depressing the plunger to return the blood to the calf.  
A collection series consisted of three syringes of blood, collected as follows.  A 60 mL syringe 
was attached to the uncapped catheter and filled over a period of 30-60 seconds, after which 
4 mL blood was rapidly transferred to each of the 13 tubes in the first array.  As soon as each 
tube was filled, it was recapped and rapidly inverted 10 times to ensure thorough mixing of the 
contents.  During this time, another 60 ml syringe was attached to the catheter and the next 
volume of blood obtained.  Once each array was completed, in approximately one minute, the 
tubes were immediately placed in their holding environment and the start time and temperature 
were recorded.  In this manner, the process was repeated to quickly obtain three complete 
replicate treatment arrays for each holding period. To facilitate the processing of samples, the 
order of draw for the separate holding periods was: 12, 6, 3, 24, 0, and then 1 h. Collecting and 
processing the samples for the three arrays in each holding period was achieved in 5 min (SD = 
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2 min).  Approximately 5 min were needed to assure readiness for the next series of blood draws, 
resulting in a spacing of 11 min (SD = 2 min) between the first syringe draws of each collection 
series. 
Ambient temperature (AMB) samples were placed in a test tube rack for holding, 
whereas chilled samples were immediately plunged into a bath of crushed ice maintained in an 
insulated portable cooler (ICE).  With respect to the chilled samples, care was taken to assure 
that only the cap and small amount of the tube remained above the ice surface.  Ambient 
temperature was recorded by a digital thermometer placed on the bench top near the samples. 
Temperature in the cooler at the ice bath/air interface was recorded from a similar thermometer 
protected in a plastic bag.  Ambient temperatures ranged from 20.3o to 21.2oC during the 1 hour 
sample collection period at the barn, then ranged from 23.9 to 25.4°C during the remaining 24 h 
holding period in the laboratory. The ice/air interface in the cooler ranged from 4.5 to 7.3°C 
during the 1 hour period while samples were being collected and ranged from 0.1 to 2.2°C, 
during the remaining holding period in the laboratory; however, the samples themselves were 
held below the ice surface where the presumed temperature at the ice/water interface was 0°C.  
Samples were either processed within 5 minutes after collection (0 h) or held 1, 3, 6, 12 
or 24 h prior to processing, which consisted of centrifuging the samples in a refrigerated unit at 
10,000 x G for 15 min.  Tubes were then removed from the centrifuge and held in an ice bath 
while plasma was harvested and divided among paired cryovials (aliquots #1 and #2) for holding 
at -70°C until analysis.  The 0 h spiked samples and the non-spiked reference samples were 
processed in the barn using the same refrigerated centrifuge utilized for the other samples.  For 
holding periods processed in the barn, the cryovials of harvested plasma were immediately 
placed in a cooler on icepacks (which had cooled overnight at -70°C), then were transported to 
the laboratory, where they were observed to have frozen during the < 10 minute transit, then 
placed in a -70°C  freezer for storage.  Samples from all other holding periods were processed in 
the laboratory, with care taken to assure similar handling as those processed in the barn. 
 
Analysis of SP1-11 and metabolites by LC-MS/MS 
Only samples held 0, 1, 3 and 6 h were analyzed by LC-MS/MS.  Analysis of aliquot #1 
samples occurred within 6 weeks after collection and storage at -70°C.    
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An LC-MS/MS method was utilized for the analysis of SP1-11, SP3-11, and SP7-11 in bovine 
plasma.  A structurally related peptide, substance P [Tyr8] was used as the internal standard for 
all analytes.  The analytes and internal standard were isolated from 0.5 mL of bovine plasma by 
solid phase extraction using HLB cartridges.   Extracts were evaporated to dryness and re-
constituted in starting mobile phase.  Electrospray ionization and MS/MS analysis was  carried 
out using an HPLC system coupled with an API 4000 Triple Quadrupole Mass Spectrometerc.  
Chromatographic separation of all analytes and internal standard was achieved using an XBridge 
Shield RP18 analytical column  and a gradient elution from 100% Mobile Phase A (0.2% Acetic 
Acid in water) to 80% Mobile Phase B (0.2% Acetic Acid in Acetonitrile) and re-equilibration 
over a 15.0 minute runtime.  The method was proven to be accurate and precise across a linear 
dynamic range from the LLOQ of 50 pg/mL to 1,000 pg/mL.   
 
Analysis of SP1-11 and metabolites by ELISA 
 Approximately 18 months following collection and storage at -70°C, aliquot #2 samples 
for all holding periods from 0 to 24 h were analyzed by ELISA.  Samples were analyzed for 
SPELISA immunoreactivity using a validated analytical method as previously described (Coetzee 
et al., 2008).  Briefly, analytes were extracted from plasma by acidifying with acetic acid and 
fractionating with reverse-phase solid-phase extraction columns.  The peptide was eluted from 
the column using an organic-aqueous solvent mixture and concentrated by drying under nitrogen.  
The dried extract was reconstituted and analyzed in duplicate according to the manufacturer’s 
instructions in the Substance P ELISA kit.a  Assay performance was monitored using 5 replicates 
of bovine plasma samples fortified with 0, 200 or 800 pg/mL of substance P purified standard.  
The method was linear across the 5 replicates at each concentration (R-squared > 0.99) and the 
coefficient of variation (CV%) at each concentration within a run was < 15%. The CV% between 
the 5 ELISA assay runs in the study was 42% for 0 pg/mL samples, 20% for 200 pg/mL samples 
and 35% for 800 pg/mL samples. 
  Statistical Analysis  
Since the three syringes of blood in each collection series were not independent, and 
because holding period was confounded with collection series, we refrained from investigating 
rates of decay and from making comparisons across holding periods.  Instead we confined our 
analysis to comparisons of the three replicates of time-by-temperature combinations within each 
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holding period.  Furthermore, because the analyses of samples by LC MS/MS and ELISA did not 
occur after the same freezer storage time and because the ELISA method cross reacts with SP 
metabolites ,we also refrained from statistical comparison of levels of SPELISA immunoreactivity 
with a summary measure of SP1-11, SP3-11, and SP7-11 analyzed by LC MS/MS.  
The response variables SP1-11, SP3-11, and SP7-11 and SPELISA were transformed (natural 
log) and analyzed using analysis of variance models.  For graphical presentation, the means and 
95% confidence intervals were transformed back to the original units.  Fixed effects included 
temperature (ICE, AMB) and enzyme inhibitor (AP50, AP500, TAB1X, TAB2X, EDTA, and 
HEP).  For analyses of SPELISA data, ELISA run was used as a random effect.  Differences 
among treatment groups were assessed using Tukey’s pairwise t-tests by time. The data analyses 
were performed using statistical software.d  Statistical significance was designated a-priori as P≤ 
0.05. 
 Results 
Non-spiked samples.  In the non-spiked blood samples which were processed 
immediately following collection, there were no detectable levels of endogenous SP1-11, SP3-11, 
or SP7-11 analyzed by LC-MS/MS.  In samples analyzed by ELISA, the level of immunoreactivity 
was in the same range as reference samples with 0 pg/mL. 
 Spiked Samples: SP1-11 SP3-11 and SP7-11 peptide analysis by LC-MS/MS.   
With respect to the ex vivo metabolism of SP1-11, SP3-11 and SP7-11, the main effects of 
holding temperature and enzyme inhibitor were significant (P < 0.0001) although there was 
marginal (P = 0.06 for SP1-11) and significant (P < 0.0001 for SP3-11 and SP7-11) evidence of an 
interaction between holding temperature and enzyme inhibitor.  Back-transformed mean 
concentrations and lettered differences are presented to show the nature of these interactions for 
SP1-11  (Figure 2), SP3-11 (Figure 3), and SP7-11 (Figure 4). 
When samples were processed at 0 h, immediately following collection, there were no 
significant differences (P > 0.12) between the mean concentrations of SP1-11,  SP3-11,  or SP7-11 
associated with any of the enzyme inhibitor treatments.   
Comparing between temperatures in samples held 1, 3, or 6 h prior to processing; the 
SP1-11 concentrations of all ICE samples within a holding period were significantly greater than 
all AMB samples (P < 0.005).   
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In ICE samples held for 1 h prior to processing, the only significant differences in SP1-11 
concentrations were between either AP500 or AP50 and the other enzyme inhibitors.  In those 
samples, the SP1-11 means of AP500 samples were greater than those of HEP, TAB2X, and 
TAB1X (P < 0.018); and the SP1-11 concentrations of AP50 samples were greater than HEP and 
TAB2X (P < 0.04).  Within the ICE samples held for 1 h, there were no significant differences in 
SP1-11 concentrations between the two levels of aprotinin, AP50 and AP500, nor between the two 
levels of protease inhibitor tablet, TAB1X and TAB2X (P > 0.99). 
 
Spiked samples: ELISA.    
Samples in all holding periods, from 0 - 24 h, were analyzed for substance P by ELISA 
(Figure 5).  The interaction term between holding temperature and enzyme inhibitor was 
significant (P < 0.0001). 
When samples were processed immediately following collection, there were no 
significant differences detected between the mean SPELISA immunoreactivity levels associated 
with any of the enzyme inhibitor treatments (P > 0.93).   
Within the 1 and 3 h holding periods, there were no significant differences between the 
mean SPELISA immunoreactivity levels of AP50, AP500, TAB1X, TAB2X, and EDTA samples 
whether held in ICE or AMB conditions (P > 0.92).  Within the 1 h holding period, the mean 
SPELISA immunoreactivity level of HEP samples was lower than that of all other enzyme 
inhibitors when held at AMB temperature (P < 0.0001) and lower than AP50 and TAB2X in 
samples held at ICE temperature (P < 0.04).  
Although not statistically comparable, levels of SPELISA immunoreactivity appeared to 
increase in samples held longer than 3 h prior to processing, reaching similar numerical levels at 
6 and 24 h as at 0 h.  Within each enzyme inhibitor group, when held at ICE temperature, the 
levels of SPELISA appeared to be lower at 12 h than at 6 and 24 h. 
 Discussion 
 This study examined the effects of enzyme inhibitor type and holding temperature during 
the period of time elapsing from the point of blood collection to the start of sample processing to 
harvest and freeze plasma destined for analysis of SP by LC-MS/MS and ELISA methodology.  
Because animals vary with regard to stress response and to the chemical, enzymatic and cellular 
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components of the blood, and because it was not possible to collect and pool whole blood from 
several individuals, only one animal was used in this study to control for this inherent source of 
variability which might otherwise have obscured differences between the in vitro treatments.  
The individual was a healthy calf, selected at random, so might be considered representative of 
its class and therefore, the use of blood from only one calf is not thought to have affected 
inferences made in this study.  Furthermore, because blood components may vary over time 
within an individual and because each holding period was associated with blood from a distinct 
point in time, we refrained from making inferences between holding periods where differences 
might have been caused by intra-individual variation.   
 As suggested by the approximately equal concentrations of SP1-11 and SP3-11 in the 0 h 
samples analyzed by LC-MS/MS, there appeared to be rapid early cleavage of parent SP1-11 to 
SP3-11 which was observed in all enzyme treatments.  Immediately after the blood was added to 
the individual test tubes, there was a short period of time, during the tube inversion process 
before the inhibitors were homogenously mixed throughout the blood sample that the enzymes in 
the blood were able to act relatively freely upon the SP1-11 peptide. This source of SP1-11 
degradation might have been minimized by spiking the tubes with exogenous SP1-11 after, 
rather than before, the addition of whole blood, but the intent of the study was to follow 
degradation due to handling procedures as if the exogenous SP1-11 had been present in the 
bloodstream.   
When samples were held at ambient temperature, enzymatic processes appeared to 
proceed more rapidly than when held in the ice bath.  Enzymes are generally known to be more 
active at physiologic temperatures than at cooler temperatures, so these results were not 
unexpected.  In samples held for 1 h, concentrations of SP1-11 analyzed by LC-MS/MS were 
approximately 50% less in ambient samples than in ice bath samples.  Even when samples were 
held in an ice bath, SP1-11 concentrations were near the LLOQ when held 3 h.  Therefore, for 
analysis of SP1-11 by LC-MS/MS, the results of our study indicated that samples should either be 
processed immediately or held in an ice bath for processing within one hour of collection.  When 
samples were processed immediately, the type of enzyme inhibitor did not significantly affect 
concentrations of SP1-11 or SP3-11.  When samples were held 1 h in an ice bath, aprotinin 
appeared to be the superior enzyme inhibitor for protecting SP1-11 from enzymatic degradation, 
and there was not a significant difference detected between the protection provided by either the 
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50 or 500 KIU/mL concentrations.  Because the composition of the complete protease inhibitor 
cocktail tablet is proprietary information, it is not known if aprotinin was included in the 
formulation, but in 1 h ice bath samples, neither the 1X nor 2X concentration of the tablet 
appeared to provide more protection of the SP1-11 peptide than EDTA alone. 
     Similar to the analysis of SP1-11 and SP3-11 by LC-MS/MS, when samples processed 
immediately were analyzed by ELISA, the type of enzyme inhibitor did not significantly affect 
levels of SPELISA immunoreactivity.  But unlike the results for LC-MS/MS, when samples were 
held for 1 or 3 h, there was no effect of temperature detected on the samples analyzed by ELISA.   
This is likely because the ELISA test measures not only the parent SP1-11 molecule, but also 
includes, to lesser extents, the family of degradation products with the SP1-11 carboxyl terminus.   
It must also be pointed out that that this study may not have had enough power to detect some 
differences between treatments with the ELISA test, given the method’s inter-assay coefficient 
of variation of 20 – 35% in the range from 200 – 800 pg/mL.  Although the ELISA test appeared 
to be relatively forgiving of holding temperature, especially when processed within the first hour, 
it is important to recognize that only the SP1-11 molecule has 100% cross reactivity with the 
ELISA test, and therefore the goal of sample handling should be to preserve the SP1-11 molecule 
to obtain the highest and most accurate concentrations.  In animal studies where a difference in 
SP between groups is the alternate hypothesis, true differences between groups might be missed 
if SP1-11 is unnecessarily allowed to degrade to SP3-11 and other metabolites which are 
measured to a lesser degree by the ELISA test.  Pronounced intra- and inter-individual variability 
of plasma SP immunoreactivity has been reported in control and in castrated calves.3 Therefore, 
in animal studies it is important to control for as much extraneous procedure-related variability 
and to measure the highest concentrations of SP1-11 as possible in order to not miss true 
differences between treatment groups due to artificially low SP immunoreactivity means paired 
with inherently high error. 
With respect to both SP1-11 and SPELISA, we could not test if the differences between the 
1 h and 0 h samples were significant, though they were often numerically large. This observation 
suggests that a strict processing order should be adhered to which follows the collection order, 
without large discrepancies in the amount of time elapsing between the times of collection and 
processing.  Otherwise, significant differences could occur due to sample-handling alone.  
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Alternately, the variability among samples may be great enough to obscure the significance of 
differences due to treatment.  
The lower concentrations of SP1-11 generally observed in all samples after the 3 h holding 
period support the recommendation that samples destined for analysis of SP should be processed 
within 1 h following collection.  Beyond 3 h from the time of collection, another factor besides 
enzymatic degradation appears to affect SP concentrations in whole blood samples in that in the 
ELISA analysis, levels of SPELISA immunoreactivity tended to rise.  Notably in the samples held 
in the ice bath for 24 h, the levels of SPELISA immunoreactivity were in a similar range as the 
samples processed immediately following collection, regardless of the enzyme inhibitor present.  
Levels of SPELISA immunoreactivity at 6 h and 12 h were variably in the same range as the 0 h 
and 24 h samples, depending upon the enzyme inhibitor.  Similarly, concentrations of SP1-11 in 
ice bath samples appeared to increase from 3 h to 6 h. 
The higher concentrations of SP in the samples held for longer than 3 h introduce the 
possibility that SP (or other molecules with cross reactivity to the ELISA test), was being 
produced by cells in the whole blood samples.  If SP was being produced in vitro, this leads to 
the question of why SPELISA concentrations at 12 h were usually less than at 6 h rather than vice-
versa.  This counter-intuitive finding might be explained by the order in which the individual 
holding periods were collected.  Notably, the samples in the 12 h holding period were from the 
first group of blood draws collected from the calf.  Although the calf was well-acclimated to the 
facility and to most of the study personnel, there was more activity than usual on the day of the 
study and the animal was unfamiliar with the person drawing blood from the catheter.  It is likely 
therefore that a certain amount of stress was involved with the procedure.  In an in vitro study of 
normal human bone marrow aspirate, it was demonstrated that the addition of ACTH (100 
ng/ml) to bone marrow stromal cells induced peak concentrations of SP at 48h post-
stimulation.17   In our study, it is possible that the samples collected first (and held 12 h prior to 
processing) contained lower levels of ACTH than those in subsequent collection series.  That 
might explain the apparent lower concentrations of SPELISA observed in samples held 12 h than 
those held 6 or 24 h, though it would have been necessary to assay levels of ACTH in the 
samples to confirm this hypothesis. 
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 Conclusion  
 This study indicated that various biological processes may affect the concentration of SP 
following blood sample collection.  Thus, to obtain the best snapshot of SP concentrations 
present in the blood at any certain time, samples should be processed as soon as possible and 
handled according to a strict protocol which ensures that all samples are immediately chilled to 
the temperature of an ice bath following sample collection.  Furthermore, it is essential that 
plasma is harvested from samples in the same order in which they were collected, with similar 
amounts of time elapsing between the point of collection and the point of plasma harvest.  
Otherwise, significant differences may occur, or be obscured, due to sample-handling technique 
alone.  This procedure is recommended when samples are to be analyzed by either LC-MS/MS 
or by ELISA.  Although the ELISA test appeared to be relatively forgiving of the holding 
temperature during the first hour after collection, the goal of sample handling should be to 
preserve the SP1-11 molecule, for which the test has the greatest cross reactivity. 
For samples destined for analysis by either ELISA or LC-MS/MS, if samples are chilled 
and processed within 5 minutes of collection, a standard blood tube containing heparin or EDTA 
appears to be as effective in preserving SP as the combination of EDTA with aprotinin or with an 
inhibitor cocktail.   
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Footnotes 
a. Assay Designs, now Enzo Life Sciences, Farmingdale, NY 
b. Complete protease inhibitor tablet, Santa Cruz Biotechnology Corp, Santa Cruz, CA 
c. AB SCIEX, Framinghan, MA 
d. SAS,Version 9.2, SAS Institute Inc., Cary, NC   
 
29 
 
 References 
1. Rushen J, Butterworth A, Swanson, JC. Animal behavior and well-being symposium: 
Farm animal welfare assurance: Science and application. J Anim Sci 2001;89:1219-1228. 
2. Malony V & Kent  JE. Assessment of acute pain in farm animals using behavioral and 
physiological measurements. J Anim Sci, 1994;75:266-272. 
3. Coetzee JF, Lubbers BV, Toerber SE, Gehring R, Thomson DU, White BJ, and Apley 
MD. Plasma concentrations of substance P and cortisol in beef calves after castration or 
simulated castration. AJVR, 2008;69:751-762. 
4. Coetzee JF, Mosher RA, KuKanich B, Gehring R, Robert B, Reinbold B, White BJ. 
Pharmacokinetics and effect of intravenous meloxicam in weaned Holstein calves following 
scoop dehorning without local anesthesia. BMC Vet Res 2012; 8:153 
5. Sutherland MA, Davis BL, Brooks TA, Coetzee JF. (2012). The physiological and 
behavioral response of pigs castrated with and without anesthesia or analgesia. J Anim Sci. 
90(7):2211-21. 
6. Theurer ME, White BJ, Anderson, DE, Miesner MD,  Mosier DA, Amrine DE, Coetzee 
JF. 2013. Effect of transportation during periods of high ambient temperature on physiology and 
behavior of beef heifers. American Journal of Veterinary Research. 74 (3): 481-490 
7. Glynn HD,  Coetzee JF, Edwards-Callaway LN, Allen KA, Dockweiler JC, KuKanich, 
Lubbers B, Fraccaro E, Jones M, Bergamasco L. The pharmacokinetics and impact of 
meloxicam, gabapentin, and flunixin in post-weaning dairy calves following dehorning with 
local anesthesia. Submitted to Journal of Veterinary Pharmacology and Therapeutics. Accepted 
January 2013. In Press. 
8. Dockweiler JC, Coetzee JF, Edwards-Callaway LN, Bello NM, Glynn, HD, Allen KA, 
Theurer ME, Jones ML, Miller KA, Bergamasco L. Effect of age and castration method on 
neurohormonal and electroencephalographic stress indicators in Holstein calves. Submitted to 
Journal of Dairy Science, Accepted April 2013. In Press. 
9.  Allen KA, Coetzee JF, Edwards-Callaway LN, Glynn, H, Dockweiler J, KuKanich B, 
Lin H, Wang C, Fraccaro E, Jones M, Bergamasco L. The impact and effect of timing of oral 
meloxicam administration on physiological responses in calves after dehorning with local 
anesthesia. Submitted to Journal of Dairy Science, October 2012. Accepted, April 2013. In Press. 
30 
 
10. Theurer ME, Anderson DE, White BJ, Miesner MD, Mosier DA, Coetzee JF, Lakritz J, 
Amrine DE. Effect of Mannheimia haemolytica pneumonia on behavior and physiologic 
responses of calves during high ambient environmental temperatures. J Anim Sci. Accepted. 
May 8, 2013.  
11. DeVane L. Substance P: A new era, a new role. Pharmacotherapy 2001;21 1061-1069. 
12. Basbaum AI, Bautista DM, Scherrer G, et al. Cellular and molecular mechanisms of pain. 
Cell, 2009;139:267-284. 
13. Chappa AK, Cooper JD, KL Audus, et al. Investigation of the metabolism of substance P 
at the blood-brain barrier using LC-MS/MS. J Pharm Biomed Anal 2007; 43:1409-1415. 
14. Ruth DM, Buckley SJ, O’Connor BF, et al. Solvent and thermal stability, and pH kinetics 
of proline-specific dipeptidyl peptidate IV-like enzyme from bovine serum. Enzyme Microb 
Technol 2007;41: 307-311. 
15. Bury RW & Mashford ML.  Biological activity of C-terminal and partial sequences of 
substance P. J Med Chem 1976;19:854-856. 
16. Komatsu T, Sasaki M, Sanai K, et al. Intrathecal substance P augments morphine-induced 
antinociception: Possible relevance in the production of substance P N-terminal fragments. 
Peptides, 2009;30:1689-1696. 
17. Maloof PB, Joshi DD, Qian J, et al. Induction of preprotachykinin-I and neurokinin-1 by 
adrenocorticotropin and prolactin. Implication for neuroendocrine-immune-hematopoietic axis.  
J Neuroimmunol 2001;112:188-196. 
 
31 
 
 Figures 
Figure 2.1.   Study Diagram. 
Blood was collected through a jugular catheter from one calf in a series of 6 separate collections.  
Each collection was comprised of 3 consecutive, closely-spaced syringe draws. One syringeful of 
blood filled one complete array of treatment tubes (6 enzyme inhibitors x 2 holding 
temperatures) spiked with SP1-11, 625 pg/mL, plus 1 non-spiked reference tube. The enzyme 
inhibitors were: 1) heparin, 15 USP/ml (HEP); 2) EDTA, 1.8 mg/mL (EDTA); 3) aprotinin, 50 
KIU/ml in EDTA (AP50); 4) aprotinin 500 KIU/ml in EDTA (AP500); 5) single-strength 
protease inhibitor tablet in EDTA (TAB1X); and 6) double-strength complete protease inhibitor 
tablet in EDTA (TAB2X).  Samples from one collection series were held in an ice bath or at 
ambient temperature (20.3 - 25.4°C) for 0, 1, 3, 6, 12, or 24 h prior to centrifugation.  Plasma was 
divided into matched samples for analysis by LC-MS/MS and by ELISA.   
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Figure 2.2.  Back-transformed least squares median concentration estimates (and upper 
95% confidence limits) of substance P (SP1-11) analyzed by LC-MS/MS.  
Whole bovine blood samples, spiked with 625 pg/mL SP1-11, were either processed 
immediately following collection (0 h, represented by gray bars), held at ambient temperature 
(23.9 – 25.4°C) or in an ice bath for 1, 3, or 6 h prior to centrifugation and harvesting of plasma. 
Sample tubes contained one of the following enzyme inhibitors: 1) heparin, 15 USP/ml (HEP); 
2) EDTA, 1.8 mg/mL (EDTA); 3) aprotinin, 50 KIU/ml in EDTA (AP50); 4) aprotinin 500 
KIU/ml in EDTA (AP500); 5) single-strength protease inhibitor tablet in EDTA (TAB1X); and 
6) double-strength complete protease inhibitor tablet in EDTA (TAB2X).  An asterisk near the x-
axis represents a sample having either no detected analyte peak or a peak below the lower limit 
of quantitation.  Within each holding period, means without a common letter are significantly 
different (P < 0.05). 
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Figure 2.3.  Back-transformed least squares median concentration estimates (and upper 
95% confidence limits) of the substance P metabolite, SP3-11,  analyzed by LC-MS/MS.   
Whole bovine blood samples, spiked with 625 pg/mL SP1-11, were either processed 
immediately following collection (0 h, represented by gray bars), held at ambient temperature 
(23.9 – 25.4°C) or in an ice bath for 1, 3, or 6 h prior to centrifugation and harvesting of plasma. 
Sample tubes contained one of the following enzyme inhibitors: 1) heparin, 15 USP/ml (HEP); 
2) EDTA, 1.8 mg/mL (EDTA); 3) aprotinin, 50 KIU/ml in EDTA (AP50); 4) aprotinin 500 
KIU/ml in EDTA (AP500); 5) single-strength protease inhibitor tablet in EDTA (TAB1X); and 
6) double-strength complete protease inhibitor tablet in EDTA (TAB2X).  An asterisk near the x-
axis represents a sample having either no detected analyte peak or a peak below the lower limit 
of quantitation.  Within each holding period, means without a common letter are significantly 
different (P < 0.05). 
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Figure 2.4.  Back-transformed least squares median concentration estimates (and upper 
95% confidence limits) of the substance P metabolite, SP7-11,  analyzed by LC-MS/MS.   
Whole bovine blood samples, spiked with 625 pg/mL SP1-11, were either processed 
immediately following collection (0 h, represented by gray bars), held at ambient temperature 
(23.9 – 25.4°C) or in an ice bath for 1, 3, or 6 h prior to centrifugation and harvesting of plasma. 
Sample tubes contained one of the following enzyme inhibitors: 1) heparin, 15 USP/ml (HEP); 
2) EDTA, 1.8 mg/mL (EDTA); 3) aprotinin, 50 KIU/ml in EDTA (AP50); 4) aprotinin 500 
KIU/ml in EDTA (AP500); 5) single-strength protease inhibitor tablet in EDTA (TAB1X); and 
6) double-strength complete protease inhibitor tablet in EDTA (TAB2X).  An asterisk near the x-
axis represents a sample having either no detected analyte peak or a peak below the lower limit 
of quantitation.  Within each holding period, means without a common letter are significantly 
different (P < 0.05). 
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Figure 2.5.  Back-transformed least squares median estimates (and upper 95% confidence 
limits) of SP immunoreactivity levels analyzed by ELISA (SPELISA).    
Whole bovine blood samples, spiked with 625 pg/mL SP1-11, were either processed 
immediately following collection (0 h, represented by gray bars), held at ambient temperature 
(23.9 – 25.4°C) or in an ice bath for 1, 3, 6, 12 and 24 h prior to centrifugation and harvesting of 
plasma. Sample tubes contained one of the following enzyme inhibitors: 1) heparin, 15 USP/ml 
(HEP); 2) EDTA, 1.8 mg/mL (EDTA); 3) aprotinin, 50 KIU/ml in EDTA (AP50); 4) aprotinin 
500 KIU/ml in EDTA (AP500); 5) single-strength protease inhibitor tablet in EDTA (TAB1X); 
and 6) double-strength complete protease inhibitor tablet in EDTA (TAB2X).  Within a holding 
period, means without a common letter are significantly different (P < 0.05). 
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Chapter 3 - Comparative effects of castration and dehorning in 
series, or concurrent castration and dehorning procedures on stress 
responses and production in Holstein calves2 
 
 Introduction 
Research assessing the physiological, behavioral and production effect of dehorning and 
castration has focused on the consequences of performing these procedures individually, with 
and without pain relief (Stafford and Mellor, 2004 and 2005).  A comparison between the 
individual procedures and the possible additive effects of their concurrent implementation, 
however, has received little attention as noted by at least one regulatory body (NAWAC, 2005).  
Yet in a survey of U.S. veterinarians in bovine practice, 90% of respondents indicated that they 
dehorn calves at the same time as castration (Coetzee et al., 2010).   
One study has investigated separate castration and dehorning procedures in the same 
calves, but the procedures were performed in series, with castration always following dehorning, 
so comparisons between procedures were confounded with order of application (Schwartzkopf-
Genswein, et al., 2005). Another study has investigated castration, dehorning, and the concurrent 
procedure, in parallel but not in series (Ballou et al., 2013; Sutherland et al., 2013.)  
                                                 
2 Reprinted with permission from “Comparative effects of castration and dehorning in series, or concurrent 
castration and dehorning procedures on stress responses and production in Holstein calves” by  R. A. Mosher, C. 
Wang, P. S. Allen, J. F. Coetzee, 2013.  Journal of Animal Science,  91:4133-4145.  American Society of Animal 
Science.  
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  The objective of the study was to compare the acute stress variables of serum cortisol 
and chute exit velocity, along with ADG as an indicator of performance and well-being 
following castration, dehorning, or concurrent castration/dehorning of calves when performed in 
parallel and in series.  The null hypothesis was that there would be no difference between 
treatments whether performed in parallel or in series.  
The methods of surgical castration and amputation dehorning, without local anesthesia or 
analgesia, were selected for this study because they were reported as the most common methods 
employed in light weight calves in the survey of U.S. veterinarians in bovine practice (Coetzee et 
al., 2010).  The results of this study are intended to provide scientific support for the 
development of best practices in the field concerning castration and dehorning of calves.   
 Materials and Methods 
This study was approved by the Institutional Animal Care and Use Committee at Kansas 
State University (Protocol # 2649).  Calves were assessed hourly for behavioral signs of 
excessive pain over a period of 10 hours after surgery, then twice daily for 7 days. Calves 
exhibiting postural changes, prolonged recumbency, anorexia or depression were scheduled to 
receive rescue analgesia with flunixin meglumine at 2.2 mg/kg IV, every 12 h. No calves were 
deemed to require rescue analgesia during the study. 
Animals and housing  
 Forty intact male horned Holstein calves, 3 to 4 months of age, were obtained from 
commercial dairy herds located in Central Kansas and allowed to acclimate for one week prior to 
study commencement in June 2009.  Upon arrival, all calves were identified with numeric ear 
tags, weighed and measured for scrotal circumference, horn length and horn base diameter 
(Table 1). These measurements were used to assess the balance of the treatment allocation in the 
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randomization process and for possible inclusion as covariates in statistical modeling. Calves 
were then vaccinated for bovine infectious rhinotracheitis, viral diarrhea, parainfluenza3, and 
syncytial virus (Bovishield Gold, Pfizer Animal Health, New York, NY).  Calves were 
administered oxytetracycline (Noromycin 300 LA, Norbrook Labs, Newry, Northern Ireland), 
IM, 3ml/100 lbs bodyweight, and doramectin (Dectomax Pour-on, Pfizer Animal Health, New 
York, NY), topically at 500 µg/kg bodyweight.  Amprolium (Corid, Duluth, GA) was added to 
the drinking water to provide 10 mg/kg PO for 5 days.  During the acclimation period, calves 
were trained on a daily basis to stand restrained by halter and lead rope tied to posts in the study 
barn while study personnel circulated among them, talking and touching the calves as would 
occur on procedure days.  
Calves were blocked by body weight and assigned to 5 pens of 8 calves each, so that each 
pen contained 2 calves from each treatment sequence.  Pens were comprised of a linear row of 
outdoor concrete pads (9.75 m x 18.29 m), each with a partial roof over straw bedding.  The diet 
consisted of water and grass hay ad libitum with a ration composed of cracked corn, oats, 
soybean meal, molasses, vitamins, and minerals delivered at 3 to 4 kg per calf per day, divided 
and offered twice daily in open bunks. Due to the nature of the diet and the housing arrangement, 
it was not possible to measure individual feed intake.  
Experimental design 
 A diagram of the two-period study is shown in Figure 1.  After an initial sham handling 
procedure, calves underwent two surgical treatments in sequence separated by approximately 2-3 
wk. The purpose of the sham procedure was to collect baseline stress-related data for each calf in 
a non-painful situation to compare to the data from the painful situation encountered in the 
surgical periods.  Thus, the sham procedure allowed each calf to act as its own historical control.  
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A period began and ended with the collection of body weight and encompassed the surgical 
treatment and the ensuing 7 days.  The two periods were separated by a balanced interim of 14 to 
21 d with a mean ± SD of 17 ± 2 d. 
The treatments within a period were: surgical castration (CAST), amputation dehorning 
with thermocautery (DH), concurrent surgical castration and amputation dehorning with 
thermocautery (CD), and control chute experience (CONT).  With subscripts indicating either 
sham handling (S) or the period (1 or 2) in which the treatment was performed, the sequences 
were: sham castration, castration, then dehorning (CASTS--CAST1--DH2); sham dehorning, 
dehorning, then castration (DHS--DH1--CAST2); and sham dehorning and castration, concurrent 
dehorning and castration, then non-surgical control (CDS--CD1--CONT2); and non-surgical 
control for Period 1 (CONTS—CONT1).  Calves in the CONT1 group participated in Period 1, 
and then were removed from the pens and from the study.   
Calves were initially blocked by receiving weight in groups of 4 and randomly assigned 
to a treatment sequence.  In order of weight, blocks were combined in pairs to form one pen. In 
Period 1, calves were processed on five separate days over 2.5 weeks, with one pen processed 
per day.  In Period 2, calves were processed on three separate days over 1.5 weeks with either 
one or two pens processed per day, which resulted in a variable number of days comprising the 
interval between treatments for different pens; however, the differences were balanced among 
treatments.   
Two days prior to the beginning of each period, calves were restrained in the chute by 
tying the head to one side of the head gate with a rope halter, then a jugular catheter was 
surgically placed using local anesthesia.  
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On the day prior to Period 1 onset, calves were subjected to sham handling in which the 
animal underwent all manipulations as if surgery were to be performed, but without making an 
incision.  Restraint of calves was conducted in the same fashion as for the jugular catheterization.  
After the first horn procedure was completed on calves in the DH and CD groups, the head was 
repositioned and tied to the other side of the chute briefly while the procedure on the other horn 
was conducted, then the head was returned to the starting position.  Sham manipulations were as 
follows: 1) sham castration (CASTS): the scrotum was washed and manipulated for 
approximately 30 seconds; 2) sham dehorning (DHS): the hair was clipped around the horns with 
electric clippers then each horn was grasped between the surgeon’s thumb and forefinger and 
manipulated for approximately 2-3 seconds; 3) sham castration combined with dehorning(CDS): 
manipulations were carried out as for calves in the CASTS and DHS groups, always in that order; 
and 4) sham control group (CONTS): calves stood restrained by the head-catch in the chute.  
Calves were processed at intervals of 8 minutes, being released approximately 5 minutes 
following the procedure.  The surgical treatments (and sham) were applied to all calves within a 
span of time approximately 1.5 h or less beginning at the same time each day.  
On D0, twenty-four hours after the sham procedure, the control animals were handled in 
a manner similar to the previous day whereas the surgically-treated calves underwent actual 
castration and dehorning.  Following cleansing of the scrotum, castration was performed by 
removing the lower one-third of the scrotum with a sterile scalpel blade; the testicles were 
exteriorized and removed by twisting and manual traction until the spermatic cord separated.  
Dehorning was achieved by placing the blades of a Barnes-type scoop dehorner around the base 
of the horn and then quickly forcing the blades together to remove the horn; bleeding was 
controlled by cauterizing the cornual vessels with a heated iron.  
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The environmental temperature was measured with a digital thermometer (Model 91551, 
Springfield, Las Cruces, NM) at 6 am (range, 16 to 27°C) and 2 pm (range, 23 to 39°C) on the 
actual procedure day for possible inclusion as a covariate in statistical modeling.   
Chute exit velocity. Following the chute restraint period, the velocity at which the calf 
exited the chute was recorded when the calf passed between two points, one meter apart, of a 
wireless infrared timing system (Polaris Multi-Event Timer, FarmTek, Wylie, TX), with the first 
device being placed 1.5 m in front of the chute headgate.  The chute exit velocity (m/s) was 
calculated by dividing the distance between the two points (one m) by the time (s) taken to travel 
the distance. 
Blood sample collection for cortisol.  Blood samples were collected through the catheter 
port during both the sham and surgical periods at the following time points after the procedure 
initiation: 5, 10, 20, 30, 40, 50, 60, 120, 240, 360, 480, 600, and 720 minutes. A baseline sample 
was taken approximately 15 min prior to the procedure, when calves were brought into the 
holding area of the barn. The 5-min sample was taken while the calf was in the chute, then the 
calf was released.  Following exit from the chute, calves were restrained with a rope halter and a 
lead long enough to allow the calf to lie down in a common holding area in the working facility 
in order to obtain blood samples from 10 to 240 min, after which time calves were released to 
their pen.  The remaining samples were obtained following restraint of the calves by rope halter 
in the pen or in the working facility. Following collection, blood samples were immediately 
transferred to tubes containing a clot activator (BD Diagnostics, Franklin Lakes, NJ) and allowed 
to clot for 30 - 60 min prior to centrifugation for 10 min at 1,500 x g.  Serum was pipetted to 
cryovials and frozen at -70°C until analysis. 
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Serum cortisol determination and calculation of summary variables.  Serum cortisol 
concentrations were analyzed in the Kansas State University Clinical Sciences Laboratory using 
a solid-phase competitive chemiluminescent enzyme immunoassay kit with an automated 
analyzer system (Immulite 1000 Cortisol, Siemens Medical Solutions Diagnostics, Los Angeles, 
CA) which has been validated for bovine plasma and serum. The assay calibration range was 28 
to 1,380 nmol/L with a lower limit of quantification of 5.5 nmol/L.  Over 21 assay runs, the 
intra- and inter-assay coefficients of variation of quality control samples with low, mid-range, 
and high concentrations were < 8.0%.  Peak cortisol concentration (Cmax), and the time at which 
peak cortisol concentration occurred (Tmax) were calculated directly from the data.  As a 
summary variable, the integrated cortisol response from baseline to 720 min, (i.e., the observed 
area under the curve, AUC0-720) was calculated using the linear trapezoidal method (Gabrielsson 
& Weiner, 2007). 
Weight.  Calves were weighed in a chute equipped with an electronic scale (EziWeigh, 
Tru-Test Corp, Aukland, New Zealand) determined to be accurate within ± 1 kg in the range 
from 100 – 250 kg.  Calves were weighed approximately 30 minutes prior to commencing the 
surgical treatments in Period 1 (Weighta) and Period 2 (Weightc), then again at the same hour 
seven days following the treatment in Period 1 (Weightb) and Period 2 (Weightd).  Calves were 
weighed immediately after rousing from rest in the morning prior to ration feeding.  Hay and 
water were freely available overnight.  Calves were also weighed on the day of the sham 
procedure for duplication of handling procedures only.   
ADG was calculated as follows for the 7 days in Period 1 and Period 2, and for the 7 to 
14 days in the interim between periods:  
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Data analysis and statistics.   
Group means for variables measured at receiving were compared using analysis of 
variance (JMP, SAS Institute, Cary, NC).  
Linear mixed models were fitted to response variables.  Models were fitted to data in the 
original scale (namely cortisol concentration, cortisol Cmax, cortisol, AUC0-720, chute exit 
velocity, and maximum eye temperature), or the log-transformed scale (namely, Tmax), as needed 
to stabilize variances and meet model assumptions.  The following explanatory covariates were 
evaluated for each model and included in the linear predictor if there was a significant 
contribution to model fit; namely horn diameter, horn length, scrotal circumference, arrival 
weight, and environmental temperatures at 6 am and at 2 pm on the treatment day.  The linear 
predictors for all statistical models except ADG included the fixed effects of treatment (CONT, 
DH, CAST or CD), period (sham, Period 1, Period 2) and their 2-way interaction. Specification 
of random effects was tailored to each model depending on convergence and estimability of 
variance components. 
The model for chute exit velocity included the random effect of the block-by-treatment 
combination to recognize the calf as the experimental unit for treatment and the blocking factor 
for period. In addition, the random effects of day, day-by-block and day-by-block-by-treatment 
were evaluated but were excluded from the final model due to their corresponding variance 
components converging to zero.  Horn base diameter was included in the final model as a 
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significant explanatory covariate (P = 0.003).  Comparisons were confined within Period because 
of increasing calf size. 
The models for Cmax, Tmax, and AUC0-720 included the random effect of day-by-block-by-
treatment to recognize the appropriate experimental unit for treatment. Random components for 
day and day-by-block combination had their variance components converge to zero and thus 
were effectively removed from the model. The residual variance covariance structure was 
modeled using a spatial power correlation structure to account for repeated measures over 
uneven time intervals.  
In addition to the fixed effects included in all models, the statistical model for cortisol 
also included the fixed effect of time (baseline, 5, 10, 20, 30, 40, 50, 60, 120, 240, 360, 480, 600, 
720 min) and all 2- and 3-way interactions with treatment and period. Random effects included 
in the linear predictor were day-by-block-by-treatment combination and day-by-block-by-
treatment-by-period combination in order to recognize the appropriate blocking factors and 
experimental units for the fixed effects of interest. The random blocking factors of day and day-
by block combination converged to zero and thus were effectively removed from the model. The 
residual variance covariance structure was modeled using a spatial power correlation structure to 
account for repeated measures over uneven time intervals. 
Average daily gain was analyzed using a general linear mixed model. The linear predictor 
in the statistical model included the fixed effects of treatment and ADG segment (Period 1, 
Interim and Period 2) and their two-way interactions.  The combinations of day-by-block and 
day-by-block-by-treatment were fitted to recognize the random blocking factor for treatment and 
its experimental unit, respectively, but both variance components converged to zero and were 
thus removed from the model. Comparisons were confined within ADG segment. 
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For all response variables, Satterthwaite's method was used to estimate degrees of 
freedom and Kenward Roger's procedure was used for the corresponding adjustments in 
estimated standard errors. Models were fitted using the GLIMMIX procedure of SAS (Version 
9.2, SAS Institute, Cary, NC) implemented using Newton-Raphson with ridging as the 
optimization technique. Model assumptions were considered to be appropriately met based on 
diagnostics conducted on studentized residuals. Estimated least square means and corresponding 
standard errors, or 95% confidence intervals, are presented. Relevant pairwise comparisons were 
conducted using Tukey-Kramer or Bonferroni adjustments, as appropriate in each case, to avoid 
inflation of Type I error rate due to multiple comparisons. 
  A significant difference was considered to exist when P ≤ 0.05, and a marginal 
difference was considered to exist if 0.05 < P ≤ 0.10.   
 Results 
No significant differences were detected between treatment groups with respect to 
weight, horn base diameter, horn length, or scrotal circumference measured at receiving (Table 
1). 
Cortisol.  Mean cortisol concentration-time profiles for treatments within period are 
shown in Figure 2.  There was a significant 3-way interaction (P < 0.0001) between treatment, 
period, and time point for serum cortisol concentrations. The P-values for selected simple effect 
comparisons are shown in Table 2; Cmax and Tmax are shown in Table 3; and AUC0-720 is shown 
in Figure 3.  For all differences between cortisol means reported below, the SED = 10 nmol/L.  
Comparisons within Period.  
Within the sham handling procedure, cortisol concentrations were significantly increased 
for CDS calves compared to CONTS and DHS calves from 5 to 30 minutes after initiation of the 
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procedure (with a difference range of 26-39 nmol/L, P ≤ 0.05), but there were no differences in 
the integrated cortisol response (AUC0-720) between the CASTS, CDS, DHS, or CONTS groups.  
The previous comparisons also included Cmax because mean maximum concentrations were 
reached in all groups within 20 min.   
Within Period 1 after the first surgical treatment, relative to the CONT1 group, cortisol 
concentrations were significantly higher from 5 to 60 min in the DH1 group (27-73 nmol/L, P < 
0.04) and from 10 to 240 min (and at 720 min) in both, the CAST1 (28-70 nmol/L, P < 0.04) and 
CD1 groups (37-95 nmol/L, P < 0.01). The previous comparisons also included Cmax because 
mean maximum concentrations were reached in all groups within 40 min; Tmax was significantly 
shorter in the CONT1 group than DH1, CAST1, and CD1 groups (P ≤ 0.01).  In contrast, there 
was no evidence for significant differences between the 3 surgically-treated groups with respect 
to Tmax, Cmax, or any cortisol concentrations during the first 40 min post-procedure.  After that 
time, cortisol concentrations in DH1 calves were significantly lower than in CAST1 calves at 120 
min post procedure (35 nmol/L, P < 0.001) and in CD1 calves from 50 to 240 min (31-46 
nmol/L, P < 0.02).  Within Period 1, cortisol concentrations were not significantly different 
between the CAST1 and CD1 groups at any time point, though there was marginal evidence that 
concentrations in the CD1 group were higher than those in the CAST1 group at 60 min 
(26 nmol/L, P > 0.06).  The AUC0-720 was significantly lower in the CONT1 group than the 
CAST1 (P = 0.002) and CD1 (P = 0.006) groups, with marginal evidence of being lower than the 
DH1 group (P = 0.07). The AUC0-720 of the CD1 group was significantly higher than the DH1 
(P = 0.006) group, but was not significantly different than the CAST1 group.   
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Within Period 2 after the second surgical treatment, relative to the CONT2 group, cortisol 
concentrations were significantly higher from 20 to 360 min in the DH2 group (35-63 nmol/L, P 
< 0.01)  and from 20 to 240 min in the CAST2 group (32-57 nmol/L, P < 0.001).  Relative to the 
CONT2 group, Cmax was significantly higher in the DH2 group (P = 0.003) with marginal 
evidence of being higher in the CAST2 group (P = 0.08); and Tmax was significantly longer in 
both  DH2 and CAST2 groups (P ≤ 0.01).  There were no significant differences between DH2 
and CAST2 calves with respect to Cmax and Tmax, however, cortisol concentrations of DH2 calves 
were significantly lower than CAST2 calves at 120 min (33 nmol/L, P = 0.005), then were higher 
from 360 to 480 min (27 to 29 nmol/L, P < 0.002).  The AUC0-720 of the CONT2 group was 
significantly lower than the CAST2 and DH2 groups (P < 0.001), but there was no significant 
difference detected between the CAST2 and DH2 groups. 
Comparisons within treatment sequence.  
Within CD1-CONT2 calves, there were no significant differences detected between the 
sham handling and CONT2 with respect to Tmax, Cmax, AUC0-720 or cortisol concentrations at any 
time point.  Within the same calves, cortisol concentrations were higher in CD1 than in both 
sham and CONT2 from approximately 20 to 360 min and at 720 min (23-76 nmol/L, P < 0.05 
except 360 min in CONT2 for which P = 0.06).  The AUC0-720 was significantly higher in CD1 
than CONT2 (P < 0.0001). 
Within DH1-CAST2 calves, compared to sham handling, cortisol concentrations were 
higher from 10 to 60 min  (33-74 nmol/L, P < 0.01) and from 5 to 240 min in CAST2 
(24-77 nmol/L, P < 0.03); and within the same calves, cortisol concentrations were higher in 
CAST2 than DH1 from 120 to 240 min (30-51 nmol/L, P < 0.001). The AUC0-720 of the sham 
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handling was significantly lower than in DH1 (P = 0.009) and CAST2 (P < 0.0001).  The AUC0-
720 in CAST2 was greater than in DH1 (P = 0.04) 
Within CAST1-DH2 calves, compared to sham handling, cortisol concentrations were 
higher from 20 to 240 min (37-78 nmol/L, P < 0.01) and from 10 to 480 min (31-84 nmol/L, P < 
0.01, excluding the 120 min time point for which P = 0.08); within the same calves, cortisol 
concentrations were higher in DH1 than CAST1 from 360 to 480 min (30-32 nmol/L, P < 0.01).  
The AUC0-720 of the sham handling was significantly lower than CAST1 (P < 0.0001).  There 
was marginal evidence that the AUC0-720 of DH2 was higher than CAST1.  
Comparisons within surgical treatment. Between CAST1 and CAST2, there was no 
significant difference between the AUC0-720, nor were there significant differences in cortisol 
concentrations between time points except at 720 min, where CAST1 was higher than CAST2 (25 
nmol/L, P = 0.02).  Between DH1 and DH2, cortisol concentrations were significantly higher in 
DH2 than DH1 at 20 min and from 240 to 480 minutes (20-26 nmol/L, P < 0.05) and the AUC0-
720 was significantly higher in DH2 than DH1 (P = 0.004).  
  Chute exit velocity. The results for chute exit velocity are shown in Figure 4. There was 
evidence of an interaction between period and treatment (P = 0.008) on chute exit velocity.  
There were no significant differences between groups when sham handled.  In Periods 1 and 2, 
calves that were castrated (CAST1 and CAST2) exited the chute significantly slower than calves 
that were dehorned (DH1 and DH2) within the respective period (P  < 0.05).     
Average daily gain.  Figure 5 shows the segmental ADG of calves through the entire 
study.  The mean ADG outcomes that were significantly different than zero were the CONT1  
group in Period 1(1.5 ± 0.4 kg/day), the CAST1 group in the interim between periods (0.9 ± 0.4 
kg/day), and the DH2 group in Period 2 (-1.2 ± 0.4 kg/day).   In Period 1, there were no 
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significant differences between the ADG of CAST1, DH1, or CD1 calves. In Period 1, the ADG 
of the CONT1 group was significantly higher than that of CD1 (difference  ± SED, 1.5 ± 0.6 
kg/day, P = 0.02), but not CAST1 nor DH1 groups.  In the interim between periods, the ADG of 
calves in the CAST1 group was significantly higher than that of the CD1 group (1.4 ± 0.6) 
kg/day, P = 0.03).  In Period 2, the ADG of the DH2 calves was significantly lower than both, 
CAST2 (-1.5 ± 0.6 kg/day, P = 0.02) and CONT2 groups (-1.8 ± 0.6 kg/day, P = 0.005).  
 Discussion 
With the aim of evaluating the relative stress and production effects of common 
husbandry procedures in the U.S. cattle industry, this study investigated the responses of surgical 
castration, amputation dehorning, and concurrent castration and dehorning of 3- to 4-month-old, 
acclimated Holstein calves.  The immediate indicators of distress  included serum cortisol 
concentration and chute exit velocity.  ADG was evaluated as a longer-term indication of 
production and overall well-being.     
Cortisol concentrations in Period 1 appeared to be most influenced by castration, whether 
performed as a solo procedure or concurrently with dehorning.  This was indicated by the mean 
cortisol concentrations of castrated calves (CAST1 and CD1) being higher than controls for 
nearly 4 h, whereas cortisol concentrations of DH1 calves were higher than controls for 
approximately 1 h. Furthermore, the overall cortisol responses of CAST1 and CD1 calves were 
not significantly different, suggesting the possibility that near-ceiling cortisol concentrations 
resulted from the castration procedure, leaving little room for an additive increase due to 
dehorning (Coetzee, 2011, Stock et al., 2013).  It is not known why cortisol concentrations of 
castrated calves were elevated above control concentrations at 720 min post-procedure in 
Period 1; that response was not observed in Period 2. 
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Important to the inferences made between groups in Period 2, the cortisol profile of 
CONT2 calves was not different than when the same calves underwent sham handling, despite an 
intervening concurrent castration and dehorning procedure.  This finding indicates the lack of a 
memory effect on cortisol concentrations in those calves in Period 2 and suggests the validity of 
their use as controls in that period.  Because all calves were were of similar breed, background, 
and acclimation, it may be assumed that the painful experience in Period 1 had a similar lack of 
memory effect on the cortisol response in Period 2, thus suggesting the validity of comparisons 
made between periods within a treatment or treatment sequence.   
Our results support and extend the findings reported by Schwartzkopf-Genswein et al. 
(2005), in which 1- to 2-mo-old Holstein bull calves were disbudded by hot iron cautery, then 
approximately 21 d later, were surgically castrated.  In that study, as in the present report, 
cortisol concentrations reached maximum peaks at approximately 30 minutes for both procedure 
groups, but then a more sustained response in the castrated calves resulted in significant 
differences  between groups in cortisol concentrations at the 120 and 240 min time points, 
similar to what we observed in calves undergoing the DH1--CAST2 sequence in our study.  
Schwartzkopf-Genswein et al. (2005) proposed that memory of a previous negative experience 
may have caused cortisol concentrations to be higher when calves were castrated than when they 
were disbudded because, in that study castration always occurred following disbudding.  
Although the previous negative experience may have contributed to the differences seen in that 
study, the apparent lack of a memory effect in CONT2 calves in our study, suggests the 
possibility of a minimum contribution.  Furthermore, when we compared cortisol response to 
castration and dehorning performed in parallel in Period 1 of our study, the results were similar, 
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with cortisol concentrations of CAST1 calves being significantly (and marginally) elevated above 
those of DH1 calves at 120 (and 240) min.   
In Period 2, with the exception of the elevated concentrations at 720 min, the cortisol 
profiles of castrated (CAST2) calves were not different than those which were castrated in Period 
1 (CAST1).  This indicates that the later castration was not more stressful than the procedure 
performed earlier.  The later dehorning procedure, however, appeared to be more stressful than 
the earlier procedure.  This is indicated by the significantly higher cortisol concentrations in the 
DH2 than the DH1 group soon after the procedure at 20 min, and later at 240 to 480 min.  
Furthermore, after the dehorning procedure, cortisol concentrations of DH2 calves did not drop to 
the level of the contemporaneous control group (CONT2) until 360 to 480 min post-procedure, 
which is in contrast to the profile noted for DH1 calves noted above.  The higher concentrations 
of cortisol in the calves dehorned in Period 2 might be attributed to the more advanced stage of 
horn development in which the horn buds had attached to the skull, and the frontal sinus was 
possibly invaded in a higher percentage of calves than in Period 1.  Horn buds are free floating in 
the skin until approximately 2 mo of age, when they gradually attach to the skull and to the 
frontal sinus (AVMA, 2011b; Stock et al., 2013). 
Regarding the concurrent castration and dehorning procedure, the cortisol concentrations 
of the CD1 group were not significantly different from those of CAST1 at any time point, but 
compared to DH1, the concurrent procedure resulted in higher cortisol concentrations for 
approximately 3 hours resulting in a higher integrated cortisol response as shown by the AUC0-
720.  In Period 2, when castrated and dehorned calves served as controls (CONT2), their cortisol 
was lower than that of calves which underwent castration (CAST2) and dehorning (DH2)  for 3.5 
h and 5.5 h, respectively. Thus, although our results indicate that castration followed by 
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dehorning is more stressful to the animal than the concurrent procedure, our results do not 
suggest a difference between the concurrent procedure and dehorning followed by castration.    It 
should be noted, however, that calves undergoing the single procedure in the field would still 
need to undergo another stressful procedure, but those undergoing the concurrent procedure 
would not require another handling such as even the chute experience of the CONT2 calves in 
our study.   
The pattern of our cortisol results observed in Period 2 were similar to the results of a 
study (reported both in Sutherland et al. (2013) and in Ballou et al. (2013)), in which calves were 
either surgically castrated or amputation dehorned as a single or combined procedure.  As 
reported in Sutherland et al. (2013), the mean cortisol concentration of dehorned calves was 
elevated above that of sham-treated controls for at least 6 h post-procedure whereas the mean 
cortisol concentration of castrated-only calves was elevated from baseline to 4h post-procedure.  
The cortisol results, as reported in Ballou et al. (2013), indicated that the cortisol concentration 
of dehorned-only calves was significantly elevated above that of castrated-only calves from 1.5 
to 6 h post-procedure.  Combining behavior with cortisol data reported both in Sutherland et al. 
(2013) and Ballou et al. (2013), in Ballou et al. (2013), the authors concluded that dehorning was 
more painful than castration in 3-mo-old calves. The results of our two-period study based upon 
cortisol results suggest that it cannot be definitively concluded from a single snapshot in time 
that one procedure is inherently more painful than another, but that the age of the animal at the 
time of application is an important determinant of pain and stress perception.  
 Baldridge et al. (2011) investigated the possibility that the relative noxiousness of a 
procedure might be associated with the calf’s desire to escape the situation, and that this might 
be measured by the velocity with which the calf left the chute.  Baldridge et al. (2011), observed 
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no difference in chute exit velocity of non-sedated Holstein calves following a sham or an actual 
surgical castration and dehorning procedure.  We observed similar results of no difference 
between the chute exit velocity of control calves and those which were concurrently castrated 
and dehorned in Period 1 of our study.  Our study extended those results to the single procedures 
of castration and dehorning, where we observed significantly slower chute exit velocities in 
CAST  than DH calves within each surgical period.  It is unknown, however if  one procedure 
was more painful than the other. Given that the chute exit velocity of DH calves was not 
significantly different (i.e. not faster) than CONT calves in any period, the difference between 
the CAST and DH calves was possibly that the CAST procedure made the calves more reluctant 
to move due to a combination of visceral pain and pain caused by moving the rear legs.  
Furthermore, given the lack of difference between the CD1 group and either CAST1 or DH1 
group it is possible that the dehorning procedure increased the desire for CD1 calves to move 
away from the chute despite any visceral pain or pain caused by movement of the rear legs.  Our 
investigation of chute exit velocity suggests that, in acclimated Holstein calves, the measure may 
be indicative of a difference in type or area of pain perception, but did not indicate that a painful 
procedure increased the desire or ability to move away from the chute faster than control calves.  
Although as reported in Baldridge et al. (2011), chute exit velocity is not useful in sedated 
calves, the measure might be a useful adjunct in assessing non-sedating methods of pain relief 
due to castration, but not dehorning. 
Surgical castration is generally followed by a period of  reduced weight gain, the severity 
of which is usually related to the age of the animal at the time of the procedure. (AVMA, 2011a; 
Bretschneider, 2005; Stafford and Mellor, 2005).  Losses in ADG following surgical castration 
tend to be greatest during the first 7 d following the procedure, though cumulative ADG may be 
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reduced through 27 to 35 days (Cohen et al., 1991; Fisher et al., 1996; Coetzee., 2013).  The 
results of our study followed that pattern, with no significant weight change detected over the 7 d 
following the single castration procedure in either Period 1 (CAST1) or Period 2 (CAST2), but 
with a significant weight gain of the  CAST1 group during the interim between procedures.  
However, given that the ADG of both CAST1 and CAST2 calves did not change significantly 
during the respective period, the CAST procedure did not appear to affect the ADG  more 
adversely when performed as a first or second procedure .  
Amputation dehorning is also generally associated with reduced weight gain following 
the procedure (AVMA, 2011b; Stock et al., 2013).  Reductions in ADG following dehorning 
have been associated with increasing age at the time of the procedure with the associated 
increasing size of the opening created in the frontal sinus (Winks et al., 1977; Brickell et al., 
2009).  The results of our study followed that pattern, with no significant weight change of the  
DH1 calves in either Period 1 or in the interim between periods.  Furthermore, when calves were 
dehorned at an older age in Period 2 (DH2) a significant weight loss was observed in the 
following 7 days, which indicates that dehorning at an older age affects the ADG more adversely 
than at a younger age.  A possible reason why we observed this difference with the DH 
procedeure, but not CAST, is the rapidly changing horn anatomy occuring in this age class of 
calves.  When a disbudding procedure is performed prior to the attachment of the horn bud to the 
frontal bone at approximately 2 months of age, the frontal sinus is not invaded, and the healing 
process may occur more quickly than when an amputation procedure must be performed in older 
calves.  As the horn grows, the horn base diameter enlarges and the likelihood of invading the 
frontal sinus increases when dehorning.  Wounds opening into the frontal sinus may take 
approximately 4 weeks to heal in calves up to one year of age (Loxton et al., 1982).  Sinusitis, 
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with associated clinical signs such as poor growth and unthriftiness, is a common sequella to 
dehorning procedures in which the frontal sinus is open and exposed to the environment 
(Mullville and Curran, 1992).   
Few reports describe weight changes following castration and dehorning performed 
concurrently.  In a study of 2- to 4-mo-old Holstein calves, Baldridge et al (2011) reported no net 
ADG over a period of 13 days following a concurrent castration and dehorning procedure.  This 
result is similar to that observed following the same procedure (CD1) in the current study. 
 
CONCLUSION 
Based on cortisol results following the first surgical treatment, castration appeared to 
elicit ceiling concentrations because the addition of the dehorning procedure did not significantly 
increase concentrations.  Whereas the cortisol response in Period 1 of DH1 calves was lower than 
CAST1 and CD1 calves for approximately 3 h during post-surgical monitoring, the chronic effect 
of dehorning appeared to be more detrimental to longer term well-being of calves than castration.  
This was shown by a significant weight gain by CAST1 but not DH1 or CD1 calves over the 
interim between periods, and by the significant weight loss in Period 2 by DH2 calves but not 
CAST2 calves. Our investigation of chute exit velocity suggests that, in acclimated Holstein 
calves, the measure may be indicative of a difference in type or area of pain perception, but did 
not indicate that a painful procedure increased the desire or ability to move away from the chute 
faster than control calves. 
Our results indicate that the order in which procedures are performed is important if there 
must be a time separation between them.  Cortisol and ADG results indicate that it is no more 
stressful or detrimental to longer term well-being to castrate first, to castrate second, or to 
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concurrently castrate and dehorn first, but that dehorning second is more stressful and 
detrimental to well-being than dehorning first.   
Thus our findings support either, the common practice of concurrent castration and 
dehorning, or the sequence of dehorning followed by castration after a healing period.  In both 
instances, however, the procedures should be initiated as early during horn development as 
possible.   
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 Figures and Tables 
 
Figure 3.1.  Study Diagram.    
Calves underwent a sham procedure followed by two sequential surgical treatments (one per 
period) separated by  2 – 3 weeks. A period began and ended with collection of body weight data 
and was of 7 days duration. With subscripts indicating indicating either sham handling (S) or the 
period in which the treatment was performed, the sequences were: sham castration, castration, 
then dehorning (CASTS--CAST1--DH2); sham dehorning, dehorning, then castration (DHS--DH1-
-CAST2); and sham dehorning and castration, concurrent dehorning and castration, then non-
surgical control (CDS--CD1--CONT2); and non-surgical control for Period 1 (CONTS--
CONT1).
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Figure 3.2.  Plasma cortisol least squares mean estimates (± SE of the estimate) for calves 
undergoing sham treatment or surgical treatments in Periods 1 and 2. 
With subscripts indicating either sham handling (S) or the period in which the treatment 
was performed, the sequences were: sham castration, castration, then dehorning (CASTS--
CAST1--DH2); sham dehorning, dehorning, then castration (DHS--DH1--CAST2); and sham 
dehorning and castration, concurrent dehorning and castration, then non-surgical control (CDS--
CD1--CONT2); and non-surgical control for Period 1 (CONTS--CONT1).  Inserts show the 
cortisol concentration-time profile for the first 60 min after the treatment initiation.  For 
graphical purposes, baseline samples are shown at 0 min.  Data are represented as treatment 
within period (and sham). 
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Figure 3.3. Least squares mean estimates (± SE of the estimate) of the integrated cortisol 
response from baseline to 720 min post-procedure (AUC0-720) for calves undergoing sham 
treatment or surgical treatments in Periods 1 and 2. 
With subscripts indicating either sham handling (S) or the period in which the treatment 
was performed, the sequences were: sham castration, castration, then dehorning (CASTS--
CAST1--DH2); sham dehorning, dehorning, then castration (DHS--DH1--CAST2); and sham 
dehorning and castration, concurrent dehorning and castration, then non-surgical control (CDS--
CD1--CONT2); and non-surgical control for Period 1 (CONTS--CONT1). 
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Figure 3.4. Least squares means (± SE of the estimate) for chute exit velocity, which was 
measured following the sham procedure and the surgical procedures in Period 1 and 2 of 
the study. 
With subscripts indicating either sham handling (S) or the period in which the treatment 
was performed, the sequences were: sham castration, castration, then dehorning (CASTS--
CAST1--DH2); sham dehorning, dehorning, then castration (DHS--DH1--CAST2); and sham 
dehorning and castration, concurrent dehorning and castration, then non-surgical control (CDS--
CD1--CONT2); and non-surgical control for Period 1 (CONTS--CONT1). 
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Figure 3.5.  Least squares mean estimates (± SE of the estimate), of ADG for calves 
undergoing sequential surgical treatments separated by  2 – 3 weeks. 
With subscripts indicating either sham handling (S) or the period in which the treatment 
was performed, the sequences were: sham castration, castration, then dehorning (CASTS--
CAST1--DH2); sham dehorning, dehorning, then castration (DHS--DH1--CAST2); and sham 
dehorning and castration, concurrent dehorning and castration, then non-surgical control (CDS--
CD1--CONT2); and non-surgical control for Period 1 (CONTS--CONT1).  Average daily gain 
was computed from weights obtained on the morning of each surgical treatment and 7 days later. 
The resulting ADG intervals and time span were: Period 1 (7 d), Interim (7 to 14 d), and Period 2 
(7 d).  Means within an ADG interval not connected by a common letter differ (P ≤ 0.05). 
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Table 3.1. Treatment sequence group means, (and SEM) of receiving data.   
With subscripts indicating either sham handling (S) or the period in which the treatment 
was performed, the sequences were: sham castration, castration, then dehorning (CASTS--
CAST1--DH2); sham dehorning, dehorning, then castration (DHS--DH1--CAST2); and sham 
dehorning and castration, concurrent dehorning and castration, then non-surgical control (CDS--
CD1--CONT2); and non-surgical control for Period 1 (CONTS--CONT1).  P-values from analysis 
of variance are shown.   
Receiving measurement 
Surgical Treatment Sequence 
P-Value CASTS- CAST1- 
DH2 
CDS- 
CD1-
CONT2 
CONTS- 
CONT1 
DHS- 
DH1- 
CAST2 
Weight, kg 144 (5) 144 (5) 145 (6) 142 (7) 0.99 
Right horn base diameter, mm 32 (3) 33 (1) 32 (2) 32 (4) 0.99 
Left horn base diameter, mm 33 (2) 33 (3) 34 (1) 34 (2) 0.98 
Right horn length, mm 35 (3) 37 (3) 35 (3) 34 (5) 0.96 
Left horn length, mm 36 (2) 35 (4) 35 (3) 34 (3) 0.97 
Scrotal circumference, cm 18 (1) 18 (1) 17 (1) 18 (1) 0.76 
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Table 3.2. P-values for selected simple effect comparisons of cortisol concentrations of 
calves undergoing non-painful handling in the sham procedure, or surgical treatments in 
Periods 1 and 2.   
With subscripts indicating either sham handling (S) or the period in which the treatment 
was performed, the sequences were: sham castration, castration, then dehorning (CASTS--
CAST1--DH2); sham dehorning, dehorning, then castration (DHS--DH1--CAST2); and sham 
dehorning and castration, concurrent dehorning and castration, then non-surgical control (CDS--
CD1--CONT2); and non-surgical control for Period 1 (CONTS--CONT1). 
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   P-value 
    Time, min 
Comparison  Baseline 5 10 20 30 40 50 60 120 240 360 480 600 720 
Within Sham 
  CASTS v. DHS 0.9 0.2 0.5 1 1 1 1 1 0.9 0.9 1 1 1 0.9 
  CASTS v. CDS 1 0.9 0.6 0.08 0.09 0.3 0.8 0.8 0.6 1 1 1 1 1 
  CASTS v. CONTS 1 0.1 0.3 0.5 1 1 1 1 0.8 1 1 1 1 0.4 
  CDS v. DHS 0.9 0.05 0.05 0.02 0.03 0.2 0.6 0.6 0.9 1 1 0.9 1 1 
  CDS v. CONTS 1 0.03 0.01 ** 0.04 0.2 0.6 0.5 1 1 1 1 1 0.7 
  DHS v. CONTS 1 1 1 0.8 1 1 1 1 1 1 0.9 1 1 0.8 
Within Period 1 
  CAST1 v. DH1 0.4 1 1 1 1 1 0.7 0.9 ** 0.07 0.9 0.8 1 0.5 
  CAST1 v. CD1 1 1 0.9 1 0.5 0.4 0.3 0.06 0.7 0.9 0.4 0.6 0.9 0.8 
  CAST1 v. CONT1 1 0.06 *** *** *** *** *** *** *** 0.02 1 1 1 0.04 
  CD1 v. DH1 0.5 1 0.9 1 0.4 0.1 0.02 * *** 0.01 0.8 1 1 0.07 
  CD1 v. CONT1 1 0.1 * *** *** *** *** *** *** * 0.2 0.7 1 * 
  DH1 v. CONT1 0.5 0.04 ** *** *** *** *** *** 0.7 1 0.7 0.8 1 0.6 
Within Period 2 
  CAST2 v. DH2 1 1 0.6 0.06 0.3 0.7 0.9 0.9 * 0.9 0.02 0.02 0.7 0.2 
  CAST2 v. CONT2 0.4 0.5 0.4 ** *** *** *** *** *** ** 0.6 0.9 0.8 0.9 
  DH2 v. CONT2 0.6 0.7 0.08 *** *** *** *** ** * * ** 0.06 1 0.1 
Within DH1-CAST2 sequence 
  DHS v. DH1 0.4 0.09 * *** *** *** *** *** 0.6 0.8 0.4 0.6 0.6 1 
  DHS v. CAST2 0.5 0.03 ** *** *** *** *** *** *** ** 0.5 1 0.1 0.7 
  DH1 v. CAST2 1 0.9 0.9 1 1 1 0.4 0.7 *** ** 1 0.7 0.5 0.5 
Within CAST1-DH2 sequence 
  CASTS v. CAST1 1 1 0.06 *** *** *** *** *** ** ** 0.7 1 0.8 0.6 
  CASTS v. DH2 0.3 0.8 * *** *** *** *** *** 0.08 ** ** * 0.6 1 
  CAST1 v. DH2 0.4 0.7 0.4 0.07 0.4 0.8 0.9 0.9 0.2 1 * * 0.9 0.7 
Within CD1-CONT2 sequence 
  CDS v. CD1 0.9 0.5 1 * *** *** *** *** *** *** 0.05 0.2 0.2 0.03 
  CDS v. CONT2 0.9 0.6 1 0.7 1 1 1 0.9 0.9 1 1 0.4 0.3 0.3 
  CD1 v. CONT2 1 0.09 1 ** *** *** *** *** *** ** 0.06 0.8 1 ** 
Within CONT1 sequence 
  
CONTS v. 
CONT1 
0.9 0.6 0.5 0.7 1 0.8 0.9 1 0.9 0.8 0.4 0.8 0.4 0.8 
Within CAST or within DH treatment 
  CAST1 v. CAST2 0.1 0.6 0.8 0.8 0.8 0.8 0.9 1 0.1 0.6 0.7 0.8 0.2 0.02 
  DH1 v. DH2 0.6 0.6 0.2 0.02 0.2 0.3 0.4 0.8 0.08 0.01 0.01 0.05 0.9 0.6 
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Table 3.3. Least squares means (and estimated  95% confidence intervals) for Cmax and the 
time at which Cmax occurred, namely  Tmax , for each treatment. 
Log transformed means for Tmax were back-transformed to the original units for 
presentation.  Serum cortisol was measured following sham handling and following surgical 
treatment in Periods 1 and 2 of the study.  With subscripts indicating either sham handling (S) or 
the period in which the treatment was performed, the sequences were: sham castration, 
castration, then dehorning (CASTS--CAST1--DH2); sham dehorning, dehorning, then castration 
(DHS--DH1--CAST2); and sham dehorning and castration, concurrent dehorning and castration, 
then non-surgical control (CDS--CD1--CONT2); and non-surgical control for Period 1 (CONTS--
CONT1). 
Treatment Cmax, nmol/L Tmax, min 
Sham  
 
 
     CONTS    73.3  (54.6 - 92.0)a 14.1  (9.8 - 21.1)ab 
     DHS   77.0  (58.3 - 95.6)a 14.5  (10.1 - 20.6)abc 
     CASTS    90.2  (71.5 - 108.9)ab 14.8  (10.4 - 21.1)abc 
     CDS 107.0  (88.4 - 125.7)bc 17.3  (12.1 - 24.7)abcd 
Period 1    
     CONT1    83.4  (64.8 - 102.1)ab 13.7  (9.4 - 19.8)ab 
     DH1 128.3  (109.7 - 147.0)cd 30.2  (21.1 - 43.0)e 
     CAST1 136.1  (117.4 - 154.8)d 26.8  (18.8 - 38.3)de 
     CD1 143.9  (125.2 - 162.6)d 34.1  (23.9 - 48.6)e 
Period 2    
     CONT2  105.8  (87.2 - 124.5)bc 11.3  (7.9 - 16.1)a 
     DH2 145.9  (127.2 - 164.6)d 23.2  (16.3 - 33.2)cde 
     CAST2 129.3  (110.7 - 148.0)cd 21.9  (15.4 - 31.3)bcde 
 
a-e. Means within entire columns (including sham, Period 1 and Period 2) not connected by the same letter are significantly (P 
< 0.05) different. 
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Chapter 4 - Pharmacokinetics of oral meloxicam in ruminant and 
pre-ruminant calves3 
 Introduction 
 
The absence of pain management for common surgical procedures, such as dehorning 
and castration of cattle, is considered to be an important animal welfare concern and is under 
consideration in the development of international trade agreements (Phillips, 2008; Thiermann & 
Babcock, 2005).    
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that is a potential 
candidate for use in providing pain relief to cattle.  As a class, NSAIDs exert anti-inflammatory 
action through variable inhibition of the cyclo-oxygenase (COX) isoenzymes which are pivotal 
catalysts in the prostaglandin production pathway.  While the expression of both COX-1 and 
COX-2 is constitutive and inducible, COX-2 is the isoform which is greatly upregulated in the 
presence of inflammatory stimuli and is therefore considered to be the desired target of NSAID 
activity (Lees, 2009).  Although the literature is deficient with respect to cattle, meloxicam is 
considered to preferentially inhibit the inflammatory effects of COX-2 while tending to spare the 
homeostatic effects of COX-1 in humans (Warner et al., 1999), dogs (Streppa et al., 2002), cats 
(Giraudel, et al., 2005), and horses (Beretta, et al., 2005). However, the relative inhibition of the 
COX isoenzymes by a drug is known to vary between species, therefore COX preference in one 
species does not guarantee similar preference in another (Lees, 2009). 
Although meloxicam is not currently approved for use in cattle in the United States, the 
drug has been approved for that use in in the European Union as well as in countries such as 
Canada, New Zealand, and Australia, which are major suppliers of beef products to the U.S 
(USDA, 2009).  Depending upon the country, approved indications variously include the use of 
meloxicam as ancillary treatment of respiratory disease, diarrhea, mastitis and/or pain due to 
dehorning or disbudding.  Based on a dose of 0.5 mg/kg bodyweight delivered intravenously or 
                                                 
3 Reprinted with permission from "Pharmacokinetics of oral meloxicam in ruminant and preruminant 
calves" by R.A. Mosher, J.F. Coetzee, C.A. Cull, R Gehring, B KuKanich. 2011.  Journal of Veterinary 
Pharmacology and Therapeutics. 35(4):373-8.  John Wiley and Sons. 
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subcutaneously, labeled withdrawal times range from 8 to 20 days for meat, and from 84 hours to 
6 days for milk (EMEA, 1999; APVMA, 2010; NZFAZ, 2010; Health Canada, 2009). 
In the U.S., although flunixin meglumine is approved for the control of pyrexia 
associated with bovine respiratory disease and for the control of inflammation and pyrexia 
associated with endotoxemia (FDA, 2003), there is currently no approved NSAID with 
indications for alleviating pain in cattle.  Provisions in the Animal Medicinal Drug Use 
Clarification Act of 1994 may therefore allow the extra-label use of meloxicam under specific 
conditions as discussed previously (Coetzee et al., 2009).  Candidate products for extra-label use 
in cattle include oral and injectable small animal formulations, and oral human formulations.   
  As determined by a study investigating the pharmacokinetics of generic human-label 
meloxicam when dosed orally to ruminant calves at 1mg/kg BW, the drug was observed to be 
well absorbed, with a mean bioavailability of 100% (Coetzee et al., 2009).  The pharmacokinetic 
properties of oral meloxicam have not been reported for pre-ruminant calves.  Due to differences 
in diet as well as differences in gastrointestinal, hepatic, and renal function, meloxicam may 
exhibit a different pharmacokinetic profile in pre-ruminant vs. ruminant calves. 
The current study was conducted in two parts.  Experiment #1 was conducted to directly 
compare pharmacokinetic differences between ruminant and pre-ruminant calves when 
meloxicam was delivered into the rumen via gavage at a dose of 0.5mg/kg body weight. 
Experiment #2 was conducted to determine the pharmacokinetic profile of oral meloxicam in 
pre-ruminant calves when the dose was suckled in milk replacer, and thus would likely bypass 
the rumen. 
 Materials and Methods 
 
This study was approved by the Institutional Animal Care and Use Committee at Kansas 
State University. 
Animals and housing 
Experiment #1: Weaned and non-weaned male Holstein calves were obtained from 
Kansas dairy herds and acclimated for 4 weeks prior to study initiation.  All calves were black 
and white Holsteins except one pre-ruminant (#31), which was a red and white Holstein. Six 
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weaned calves, 4-7 months old, and weighing 95-168 kg at time of study were classified as full 
ruminants and were group-housed on an outdoor concrete pad (9.8 m x 18.3 m) with a partial 
roof over straw bedding.  Six unweaned calves, 6-8 weeks old and weighing 62-89 kg at time of 
study were classified as pre-ruminants and were similarly housed nearby in individual 
contiguous enclosures (1.6 m x 5.3 m) constructed with wire panels.  Ruminant calves were 
maintained on water and grass hay ad libitum and supplemented with a typical receiving diet 
composed of cracked corn, oats, soybean meal, molasses and a protein/vitamin/mineral 
supplement at 6-8 kg/ head/ day.  Pre-ruminant calves were primarily maintained on a bucketfed 
milk replacer diet, fortified with vitamins and minerals, and containing a minimum of 20% crude 
fat and 25% crude protein derived from milk (first 5 ingredients) and soy protein (Maxicare, 
Land O’Lakes, MNWater (in a bucket) and calf starter ration (Herd Maker Supreme B90, Land 
O’Lakes, MN) were offered ad libitum throughout the acclimation period and during the study.    
Upon arrival, study animals were identified with numeric ear tags, vaccinated (Bovishield Gold, 
Pfizer Inc., NY, NY), and administered oxytetracycline (Noromycin 300 LA, Norbrook 
Laboratories, County Down, Northern Ireland) IM, 9 mg/kg bodyweight. All calves were 
surgically castrated 1-2 weeks after arrival and allowed to heal for a minimum of 10 days prior to 
the study.      
At study initiation, the mean (± standard deviation) weights of the ruminant and pre-
ruminant groups were 129.2 ± 32.3 kg and 75.5 ± 9.3 kg respectively.  Weights for dose 
calculation were determined by weighing the calves 24 hours prior to treatment administration.  
Calves were re-weighed on the morning of the study commencement for determination of the 
administered dose.    
  Experiment #2:  Six Holstein bull calves, 18 – 28 days of age, with mean (± standard 
deviation) weight of 46.4 ± 10.5 kg, born at the KSU Dairy Unit, were maintained in their 
accustomed individual housing units (1.2m x 4m) comprised of a covered hutch with attached 
outside exercise area.  Diet consisted primarily of bottle-and-nipple-fed milk replacer, fortified 
with vitamins and minerals, and containing a minimum of 18% crude fat and 28% crude protein 
derived from milk products (Mother’s Pride, Ridley Inc, Mankato, MN). Water (in a bucket) and 
starter ration (Super Krunch 22% Calf Starter, Ridley Inc, Mankato, MN), were offered ad 
libitum during the study.    
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Experimental design  
  Experiment #1 was a parallel design with rumen development classification as the 
explanatory variable, and with pharmacokinetic parameters as the response variables.  All calves 
received meloxicam, PO, at a target dose of 0.5 mg/kg.   
Approximately 24 hours prior to study commencement, calves were restrained with a 
head gate and halter for intravenous catheter placement.   The area over the jugular vein was 
clipped and surgically prepared with alternating scrubs of 70% isopropyl alcohol and povidone 
iodine. The catheter site was infiltrated with 2% lidocaine injection, 1 mL s.c., (Hospira Inc, 
Lake Forest, IL) prior to making a stab incision with a #22 scalpel blade.  Using sterile 
technique, a 14 G x 130 mm extended use catheter (MILACATH®, MILA International, 
Florence, KY) with injection plug (SURFLOW®, Terumo, Somerset, NY)  was inserted into the 
right jugular vein and sutured to the skin using #3 nylon suture (Braunamid®, Braun, Bethlehem, 
PA).  Catheter patency was maintained by flushing with 3 mL of a heparin saline solution 
containing 3 USP units heparin sodium/mL saline (Heparin Sodium Injection, Baxter Healthcare, 
Deerfield, IL).     
Neither food nor water was withheld at any time during the study; pre-ruminants were 
bucket-fed their usual quantity of milk replacer 30 minutes prior to dosing.  
Meloxicam was administered orally at 0.5 mg/kg (Meloxicam tablets 15 mg (NDC 
60505-2554-1), Apotex Corp, Weston, FL; Lot # JD9485).   The dose was rounded to the nearest 
whole tablet and was based upon body weight obtained 24 hours prior to study.  Tablets were 
crushed and mixed in 50 mL of tap water within 5 minutes of administration.   After passing a 
stomach tube with the aid of a Frick speculum, one operator blew air into the tube while another 
listened through a stethoscope placed over the rumen to assure placement within the 
gastrointestinal (GI) tract.  The drug suspension was delivered through the stomach tube and then 
chased with 300 mL of water.  Air was then blown through the tube to empty all fluid contents 
into the GI tract prior to removal.  
Approximately 6 mL of blood was collected through the catheter port at 0 and 30 minutes 
and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36, 48, 60, 72, 96 and 120 hours after administration.  
Prior to blood sampling, calves were temporarily restrained with a rope halter and the catheter 
cap cleaned with 70% isopropyl alcohol.  The heparin lock solution was flushed from the 
catheter before each collection by twice drawing 5 mL of blood into the syringe and then 
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returning it to the calf through the catheter.  Blood drawn into the syringe on the third pull was 
immediately transferred to a lithium heparin vacutainer tube (BD Diagnostics, Franklin Lakes, 
NJ).  Samples were stored on ice prior to centrifugation for 10 minutes at 1,500 x g within 30 
minutes of collection. Plasma was then pipetted into cryovials and frozen at -70°C until analysis. 
Experiment #2.  With the exception of the dose delivery method, the second experiment 
was carried out as described above.  The crushed tablets were suspended in the morning ration of 
rehydrated milk replacer and offered to the calves in nipple bottles as they were accustomed to 
feeding.   Following consumption of the contents, the bottle was rinsed with 100 mL of water 
and reoffered to the calves.  Dose and rinse water were readily consumed by all calves within 5 
minutes of feeding initiation. 
 Plasma drug analysis 
 Plasma concentrations of meloxicam (m/z 352.09→114.90) were determined with high-
pressure liquid chromatography (Shimadzu Prominence, Shimadzu Scientific Instruments, 
Columbia, MD, USA) and mass spectrometry (API 2000, Applied Biosystems, Foster City, CA, 
USA). Plasma samples or standards (100 μL) were added to 100 μL of internal standard 
(piroxicam 0.5 μg/mL in methanol, m/z 332.12→95.10) and 300 μL of methanol with 0.1% 
formic acid to precipitate the proteins. The samples were vortexed for 5 seconds and centrifuged 
for 10 minutes at 10,000 x g. The supernatant, 200 μL, was transferred to an injection vial with 
the injection volume set to 10 μL. The mobile phase consisted of A: acetonitrile and B: 0.1% 
formic acid at a flow rate of 0.4 mL/min. The mobile phase consisted of 85% B from 0 – 0.5 
minutes with a linear gradient to 50% B at 2.5 minutes which was maintained until 3 minutes, 
followed by a linear gradient to 85% B at 4 minutes with a total run time of 5 minutes. 
Separation was achieved with a C8 column (Supelco Discovery C8, 50 mm x 2.1 mm x 5 μm, 
Sigma-Aldrich, St. Louis, MO, USA) maintained at 40o C. With a limit of quantification of 0.025 
μg/mL, the standard curve was linear from 0.025 μg/mL to 10 μg/mL and was accepted if the 
correlation coefficient exceeded 0.99 and predicted values were within 15% of the actual values. 
The accuracy of the assay was 103 ± 7% of the actual value and the coefficient of variation was 
7% determined on replicates of 5 each at 0.025, 0.5, and 5 μg/mL. 
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 Pharmacokinetic and statistical analysis  
 Noncompartmental (NCA) and compartmental (CA) pharmacokinetic analyses were 
performed with computer software (WinNonlin 5.2, Pharsight Corporation, Mountain View, CA, 
USA).  The pharmacokinetic parameters were estimated based upon the actual dose administered 
to individual calves. Maximum serum meloxicam concentration (Cmax) and time to maximum 
serum concentration (Tmax) were obtained directly from the data.  The parameters calculated with 
NCA included the plasma clearance per fraction of dose absorbed (Cl/F); the first order 
elimination rate constant (λz); and terminal half-life (t½ λz;).  The observed area under the curve 
extrapolated to infinity (AUCinf) was calculated using the trapezoidal rule to calculate AUC to 
the last observed concentration (Clast), then adding the extrapolated portion beyond that point as 
follows: 
 
 The apparent volume of distribution per fraction of the dose absorbed based on the terminal 
phase (Vz/F) was calculated by the following equation: 
 
The fit of compartmental models was compared by inspection of residuals, the Akaike 
Information Criterion, and the Schwarz Bayesian Criterion (Gabrielsson & Weiner, 2009).  A 
one-compartment model with no lag time, with weighting of 1/(predicted-C)2 was determined to 
best fit the data. The parameters estimated through compartmental modeling of mean data 
included the absorption rate constant (K01); the elimination rate constant (K10); and apparent 
volume of distribution per fraction of the dose absorbed (V/F).  The data were fit to the following 
one-compartment model with no lag time and with weighting of 1/(predicted C)2 : 
 
where Ct  is plasma concentration at time, t; and D is administered dose. 
Statistical analyses were performed using JMP (SAS Institute Inc, Cary, NC); P-values of ≤ 0.05, 
were considered statistically significant. The normality assumption was tested for each variable 
set with the Shapiro-Wilk W test.  Group means from the normally distributed variables, AUC, 
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Tmax, λz, and dose were compared by one-way analysis of variance.  When significant differences 
were detected, pairwise comparisons were performed using the Tukey-Kramer HSD method to 
protect the experiment-wide level of significance.  Means of the non-normally distributed 
variables, Cl/F, Cmax, t ½ ,Vz/F, K01, K10 were compared using a Kruskal-Wallis nonparametric 
one-way analysis of variance.  When significant differences were detected between means within 
the group, pairwise comparisons were performed with the Wilcoxon two-level nonparametric test 
to determine which pairs were different. 
Upon initial inspection of the data, the pharmacokinetics of meloxicam in Calf #31 in the 
PRG group appeared to be different from the rest of the PRG group.  For that reason all 
statistical analyses were performed both with, and without, Calf #31.  Although the PK 
parameters, Cl/F, λz , AUCinf,  Cmax, MRT and t½λz  for Calf #31 were group extremes which 
biased the mean, the exclusion of that calf’s data did not result in a change in the outcome of 
significance tests, so data were not excluded.  
 Plasma chemistry analysis  
 Experiment #1.  To investigate the post hoc hypothesis that hypoproteinemia might have 
affected the pharmacokinetics of meloxicam in Calf #31 in the PRG group, archived plasma 
samples obtained immediately prior to dosing calves in the first experiment were submitted to 
the Kansas State University Diagnostic Laboratory for analysis of albumin, globulin, and total 
protein.  Analysis was performed using an automated, software-controlled system (Cobas 6000 
analyzer, Roche Diagnostics, Switzerland). 
 
 Results  
All calves in the first experiment were determined to have normal levels of plasma 
proteins.   
There was not a significant difference between the dose (mean ± SD; range) of 
meloxicam administered to calves within the groups: PRF (0.530 ± 0.131, 0.350-0.650 mg/kg), 
PRG (0.509 ± 0.007; 0.497 – 0.518 mg/kg), and RG (0.515 ± 0.018; 0.5 – 0.545mg/kg). There 
were quantifiable levels of meloxicam in the plasma of all calves at the first timepoint, 30 
minutes after dosing.  The model-predicted time-concentration curve with observed mean ± SD 
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concentration for each group is shown in Figure 1.  The figure highlights the greater variation in 
plasma concentration observed among the PRG calves than in the other groups. In Calf #31, of 
the PRG group, the plasma concentration of meloxicam was below the limit of quantification by 
96 h.    For comparison, the predicted curves are overlayed without SD bars in Figure 2. 
Summary estimates of pharmacokinetic parameters obtained through NCA are presented 
in Table 1.  The only significant difference revealed by NCA occurred between the two pre-
ruminant groups.  Cmax was lower (P=0.03) in PRF (1.27 ± 0.430 µg/mL) than PRG calves 
(2.20 ± 0.467 µg/mL), while Cmax of RG calves (1.95 ± 0.955 µg/mL) was not different from 
other groups.   There was a difference (P = 0.055) in Vz/F of the PRF calves (337 ± 78 mL/kg) 
and the PRG calves (211 ± 75 mL/kg).  Noncompartmental pharmacokinetic parameters 
associated with Calf #31 in the PRG group represented the group minima for AUCinf, Cmax, 
MRT and t1/ 2λz and the group maxima for Cl/F and λz .   
Summary estimates of the pharmacokinetic parameters obtained by fitting the data to a 
one-compartment model are presented in Table 2.  Estimates of V/F were significantly different 
between the PRF group (365 ± 57 mL/kg) and both the PRG (177 ± 63 mL/kg, P < 0.01) and the 
RG (232 ± 83 mL/kg, P = 0.01) groups.  Whereas compartmental modeling revealed a significant 
difference (P < 0.01) between the rate of absorption in the PRF (0.237 ± 0.0478 h-1) and RG 
(0.0815 ± 0.0188 h-1) groups, there was no difference between the K01 estimates for either of 
those groups and that of the PRG group (0.153 ± 0.128 h-1). Compartmental pharmacokinetic 
parameters associated with Calf #31 in the PRG group represented the group maxima for Cl/F 
and K10 and the minimum for AUCinf.  
 Discussion 
Between the two experiments described in this study, we examined the pharmacokinetics 
of meloxicam in 1) ruminant calves dosed orally via gavage, 2) pre-ruminant calves dosed orally 
via gavage, and 3) pre-ruminant calves dosed orally by mixing the drug in the usual ration of 
milk-replacer.  The pharmacokinetic parameters of oral meloxicam in the ruminant calves in the 
current study were similar to those reported earlier (Coetzee et al., 2009).   
Upon analyzing the results of the first experiment in this study, there were no significant 
differences apparent between the PRG and RG groups.  It was noted, however, that the t½ λz of 
meloxicam was much shorter in Calf #31 (9.73 h) in the PRG group than the group mean (40 h).  
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Since meloxicam is highly bound to plasma albumin, and thus its availability for renal excretion 
is limited, it was initially considered that the relatively short t½ λz of meloxicam in Calf #31 might 
be due to low levels of albumin in the bloodstream.  To test this hypothesis, archived samples of 
plasma obtained immediately prior to dosing were analyzed, but revealed no evidence of 
hypoalbuminemia.  It was also considered that the shorter t½ λz in that particular calf may have 
been due to the calf reflexively closing the reticular groove during dosing and causing the drug to 
bypass the rumen.  To test this hypothesis, the second experiment was conducted to evaluate the 
pharmacokinetics of meloxicam in calves when the dose was delivered in a manner likely to be 
delivered directly to the abomasum.  The minimum t½ λz value observed in the PRF group 
however, was 27.3 h, which was similar to the minimum observed in the RG group of 22.8 h, so 
it was considered unlikely that the short t½ λz observed in Calf #31was due to the drug simply 
bypassing the rumen.  The reason for the shorter t½ λz in that calf was not definitively determined, 
though a possible explanation could be increased metabolic enzyme activity in that individual.  
This supposition is supported by Calf #31 exhibiting the group minimum Cmax, the group 
maximum Cl/F, yet the Vz/F was not an extreme value.  
Of note, Calf #31 was the only Holstein of red color in the study.  The red color in the 
Holstein breed is a recessive trait, with black being the dominant color.  Thus a red Holstein 
carries two copies of the gene for red color, whereas a black Holstein may carry two copies of 
the gene for black color, or may carry one for each color (Specht, 2009).  It is not known if there 
was a genetic association between the coat color of Calf #31 and what appeared to be an 
increased rate of drug metabolism.  As shown in Table 3, the pharmacokinetics of meloxicam in 
black Holstein calves in an IV/PO randomized crossover study (Coetzee et al. 2009) were of 
similar range to those in the current study. When meloxicam was given orally to 6 beef calves of 
mixed breed origins, the ranges for Cl/F, Vz/F, and t1/ 2λz were similar to those seen with black 
Holstein calves, with the exception of a minimum t1/ 2λz value of 8.4 h which is similar to that of 
the red Holstein (Calf #31, 9.7 h) in the current study.  Therefore, Calf #31, while initially 
appearing to be a possible outlier, may represent a population of calves with increased 
metabolism. 
In cattle, meloxicam is at least 96.5% bound to plasma proteins (EMEA, 1999) and must 
undergo extensive hepatic biotransormation to be eliminated from the body (Busch et al., 1998).  
In humans, meloxicam  is metabolized by peroxidase and by two enzymes in the cytochrome 
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P450 monooxygenase superfamily, CYP2C9  and CYP3A4  (Boehringer-Ingleheim, 2010).  
Both CYP2C9-like and CYP3A4 catalytic activity is expressed in the bovine liver (Ioannides, 
2006).    Meloxicam metabolites detected in cattle are pharmacologically inactive and include 
those found in other species (5’-hydroxymethyl-, 5’-carboxy-, and oxalyl- metabolites) as well as 
an additional polar metabolite (EMEA, 1999).  CYP450 genes are highly polymorphic and recent 
studies of select CYP450 genes in cattle indicate differences in transcription between sexes and 
between the breeds studied (Ashwell et al., 2011; Giantin et al., 2008).  Such differences may 
underlie the relatively short t½ λz of the red Holstein (Calf #31) in the current study and of the 
beef calf in Coetzee et al., 2009.          
PK data from the PRF group were statistically compared to that of the PRG and RG 
groups, although the experiments were conducted in trials approximately one month apart in 
separate facilities.  And although the PRF and PRG groups both had immature rumen 
development and were consuming regular feedings of milk replacer, the PRF calves were 18 to 
28 days of age whereas the PRG calves were 6-8 weeks of age.  Furthermore, the milk replacer 
fed to the pre-ruminant groups was of two different brands.  Due to these uncontrolled factors, 
statistical comparisons should be interpreted with caution, but they do allow us to make certain 
interpretations and conjectures which may be useful clinically and for future controlled studies. 
  In the second experiment, when the dose was delivered to pre-ruminant calves through suckling 
a suspension of drug in milk replacer, and thus directly entering the abomasum, Cmax was lower 
and V/F was higher than in the gavaged pre-ruminants. In comparison with the gavaged ruminant 
calves, the PRF group estimate of V/F was higher and K01 was faster.  These differences between 
the suckled group and the gavaged groups were likely due largely to differences in 
bioavailability created by the delivery of drug into different stomach compartments and by a 
probable food-drug interaction with milk-replacer in the PRF calves.    
 There was greater variability in pharmacokinetic parameter estimates between individuals 
within each of the pre-ruminant groups than between individuals within the ruminant group.  
This increased variability within the pre-ruminant groups may have been due to a combination of 
factors such as amount of starter ration and/or milk replacer consumed on the day of dosing, the 
presence of undiagnosed enteric pathology, differences in maturation of the hepatic metabolic 
enzyme system, differences in rumen maturity, and closure kinetics of the reticular groove while 
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consuming the dose in milk replacer. (De Backer & Debackere, 1979; Marriner, 1979; 
Nouws,1992).  
  The V/F of PRF calves was higher than that of both PRG and RG calves.  Unless 
combined with an IV study, the fraction of the dose absorbed cannot be estimated with extra-
vascular PK models, and so cannot be entered into calculations of clearance and volume of 
distribution.  Therefore, those parameters are reported relative to the fraction of the dose 
absorbed.  Thus, the difference in V/F noted between groups may be a result of differences in 
volume of distribution and/or bioavailability.  It is unlikely, especially when comparing the pre-
ruminant groups, that the volumes of distribution are greatly different, making the observed V/F 
differences more likely due to bioavailability issues.  Differences in hepatic maturation could 
explain how significant differences in V/F could occur due to bioavailability, yet Cl/F could be 
similar between all groups.  If Cl and F were both reduced in the PRF group, the ratio of Cl/F 
could remain similar to groups with higher Cl and F.  The lower Cmax observed in the PRF 
group with respect especially to the PRG group supports the premise of a lower bioavailability in 
the former group. 
In addition to anatomic differences, pre-ruminant and ruminant calves differ in the 
constancy of abomasal pH, which may affect the drug absorption process.  Meloxicam is a weak 
acid which is nearly insoluble in water and has a peak liquid-aqueous partition coefficient of 2.68 
at pH 3 (Luger et al., 1996). Thus absorption of the drug is favored in relatively acidic areas of 
the ruminant gastrointestinal tract.  Although pH in the rumen may range from approximately 5.5 
– 7.0,  it is likely that little absorption of meloxicam occurs in that compartment, with the rumen 
serving mostly as a reservoir for extended release of drug into the remaining gastrointestinal 
tract. In studies of acetaminophen, which is unionized at physiological pH, an insignificant 
amount of the drug was absorbed from the rumen (Schaer et al., 2005).  In the non-fasting 
ruminant calf, the constant flow of ingesta from the forestomach compartments results in a 
relatively stable pH value of about 2.1 - 2.2 in the abomasum.  In the pre-ruminant calf 
maintained primarily on a diet of milk or milk-replacer, the abomasal pH is much more variable 
depending upon the time relative to feeding.  Immediately following suckling, the abomasal pH 
quickly rises to approximately 6, depending upon the pH of the ingested milk or milk-replacer, 
after which the pH remains relatively constant for up to 2 h, then as the milk curd is digested, 
gradually declines over 7-9 h to reach pre-prandial values in the pH range of 1-2 (Church, 1993; 
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Constable et al., 2006).   In the current study, although both pre-ruminant groups ingested milk 
replacer in the peri-dosing period, and would have likely experienced a similar rise and fall of 
abomasal pH, the time differential in dosing relative to feeding may have resulted in a great 
enough offset of the pattern that the pH environment in the GI tract was less conducive to 
absorption in the PRF group than either of the gavaged groups.   
  Although the pre-ruminant groups consumed different brands of milk replacer, another 
difference was in the timing of consumption relative to administration of the meloxicam dose.  
While the PRF calves consumed milk replacer at the same time as the drug, PRG calves 
consumed their ration approximately 30 minutes prior to dosing.  There is considerable variation 
in extent of curd formation between and within brands of milk replacer. (Okada et al., 2009;  
Heinrichs et al., 1995).  We might, however, assume there was at least some curd formation in 
the PRF and PRG calves in this study, since the primary ingredients of both milk replacers were 
dried milk products (Heinrichs et al., 1995).  In an in vitro coagulation study, after 
acetaminophen was mixed with milk and allowed to clot, it was found that the dose was divided 
into approximately equal halves between the curd and whey portions (Herrli-Gygi et al., 2008).  
Likewise, in the PRF calves of the current study, a portion of the meloxicam dose would likely 
have been trapped within the curds as they formed, whereas the remaining portion of the dose 
was available to pass into the small intestine for early absorption with the whey fraction.  The 
meloxicam which was bound within the curd would have been released for absorption as the 
curd was slowly digested.  With the PRG calves however, most of the curd was likely already 
formed by the time the dose of meloxicam was administered.  Thus, as the drug entered the 
abomasum from the rumen of the PRG calves, most of the dose likely flowed past the curd and 
was available for absorption in the small intestine.   
In calves, past studies with ampicillin, penicillin, tetracycline, chloramphenicol, 
trimethoprim, and acetominophen showed lower bioavailability when fed suspended in milk 
replacer compared to water (Nouws, 1992; Schaer et al., 2005).  Proposed mechanisms included 
chelation with calcium and/or binding to milk proteins. The literature is deficient in studies 
investigating the bioavailability of meloxicam administered in electrolyte or milk replacer 
formulations, but inferences might be drawn from the current study.  Considering that a fraction 
of the meloxicam dose may have been bound in curd in the PRF calves, this could explain the 
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apparent lower bioavailability with respect to the PRG calves which also received milk in the 
peri-dosing period. 
Although the rates of absorption in the pre-ruminant calves were both numerically greater 
than the K01 of the ruminant group, only the PRF and RG groups were significantly different.  
This is likely due to the delivery of meloxicam into the rumen of calves in the PRG and RG 
groups, whereas in the PRF group, most of the dose likely bypassed the rumen and was delivered 
into the abomasum.  Therefore, different rates of oroduodenal passage would have occurred, with 
the greatest portion of the difference likely occurring in the passage of drug from the rumen to 
the abomasum.  A radiographical imaging study showed that outflow of fluids delivered to the 
rumen of pre-ruminant calves occurred mostly within 3 hours (Lateur-Rowet & Breukink, 1983).  
With respect to adult ruminant cattle, one study indicated ruminal turnover rates for liquid, grain, 
and hay as 8.1, 4.4, and 3.9 percent per hour (Hartnell & Satter, 1979).  Thus, although 
meloxicam was detected in the plasma of all groups at 30 minutes post-dosing, the rate of 
passage from the rumen into the abomasum and small intestine was likely the limiting factor 
which resulted in the lower rate of absorption seen in the RG group vs. the PRF group. 
 
 Conclusion 
Oral delivery of meloxicam may be useful in administering analgesia prior to surgical 
procedures such as dehorning and castration of calves.  Meloxicam can be successfully 
administered to pre-ruminant calves through feeding a suspension of drug powder in the usual 
ration of milk-replacer, though peak plasma concentrations may be reduced due to possible 
interaction with curd-forming proteins.  This may possibly reduce therapeutic response.  Also, 
Part 530 of Title 21 in the Code of Federal Regulations, which implements the AMDUCA, 
prohibits extra-label use of a drug in or on an animal feed (FDA, 21CFR.530).  For both of those 
reasons, it may be preferable to administer oral meloxicam to pre-ruminant calves in a manner 
which causes the drug to enter the abomasum after milk proteins have clotted.  This could be 
achieved, by delivering the dose directly into the rumen following feeding, as in the current 
study, or by waiting 1-2 hours after feeding before offering the dose in a non-clotting carrier to 
be suckled.  A commonly suggested conservative withdrawal period for an extra-label drug used 
in a food animal, is 10 terminal half-lives (Riviere & Sundlof, 2009). Based upon the largest 
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mean terminal half-life of 40 h observed in this study, a withdrawal period of 20 days might be 
recommended following the oral dosing of meloxicam to pre-ruminant calves. 
Although plasma concentration profiles are more variable in pre-ruminants, the total drug 
exposure, as indicated by the AUC, is similar to that of older ruminant calves. Controlled studies 
are necessary, however, to determine if differences in relative bioavailability exist between 
dosing oral meloxicam at various times, before, during, and after feeding milk replacer.  Further 
study is also needed to determine if any resulting differences are clinically significant.  
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 Figures and Tables  
 
Figure 4.1.  Plasma meloxicam concentration (mean + SD) following single 0.5 mg/kg PO 
administration to ruminant calves via gavage (RG), pre-ruminant calves via gavage (PRG) 
and pre-ruminant calves via feeding in milk replacer (PRF).  
 Solid lines represent group mean concentration fit to a one compartment model, with 
weighting of 1/(predicted C)2.   In the PRG group, plasma meloxicam concentration was below 
the limit of quantitation for Calf #31 at 96 and 120 h. 
 
92 
 
Figure 4.2.  Group mean concentration fit to a one compartment model, with weighting of 
1/(predicted C)2  of plasma meloxicam concentration following a single 0.5 mg/kg PO 
administration to ruminant calves via gavage (RG), pre-ruminant calves via gavage (PRG) 
and pre-ruminant calves via feeding in milk replacer (PRF). 
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Table 4.1.  Pharmacokinetic parameters obtained from non-compartmental analysis of 
meloxicam after single 0.5 mg/kg PO administration in pre-ruminant calves dosed via 
ingested milk (PRF) or via gavage (PRG) and ruminant calves via gavage (RG).   
 Within a column, superscripts not containing the same letter denote a significant 
difference between associated parameter means (P < 0.05).  Similarly, symbols denote a nearly 
significant difference (P=0.055).  †Pharmacokinetic values for Calf #31 in the PRG group which 
are extremes. 
Parameter Group Mean SD Minimum Median Maximum 
              
AUCinf PRF 85.4 46.6 49.6 69.7 179.0 
(h*µg/mL) PRG 151.0 80.2 39.6† 193.0 218.0 
  RG 86.7 28.9 54.2 83.0 137.0 
              
Cl/F PRF 6.92 2.10 3.66 7.26 9.74 
(mL/h/kg) PRG 5.28 4.52 2.34 2.63 13.10† 
  RG 6.45 1.92 3.80 6.45 9.28 
              
Cmax PRF 1.27 a 0.430 0.726 1.29 1.79 
(µg/mL) PRG 2.20 b 0.467 1.630† 2.37 2.65 
  RG 1.95ab 0.955 1.020 1.85 3.74 
              
 λz PRF 0.0206 0.0051 0.0118 0.0209 0.0254 
(h-1) PRG 0.0256 0.0229 0.0106 0.0169 0.0713† 
  RG 0.0238 0.0045 0.0188 0.0238 0.0304 
              
MRT PRF 58.4 17.5 42.4 52.9 91.4 
(h) PRG 63.5 29.4 20.5† 70.5 98.8 
  RG 50.3 8.3 41.1 49.5 59.8 
              
t½ λz PRF 36.0 11.7 27.3 33.3 58.5 
(h) PRG 40.0 19.8 9.7† 41.2 65.3 
  RG 29.9 5.6 22.8 29.1 37.0 
              
Tmax PRF 14.3 6.7 6.0 14.0 24.0 
(h) PRG 17.0 7.0 6.0 18.0 24.0 
  RG 17.3 6.3 10.0 18.0 24.0 
              
Vz/F PRF 337 ▲ 78 289 313 495 
(mL/kg) PRG 211  ●   75 140 185 340 
  RG 281●▲ 103 156 304 407 
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Table 4.2.  Pharmacokinetic parameters obtained from fitting a one-compartmental model, 
with no lag time, and with weighting of 1/(predicted C)2 to data obtained from 
administering oral meloxicam, 0.5 mg/kg,  to pre-ruminant calves dosed via ingested milk 
(PRF) or via gavage (PRG) and ruminant calves via gavage (RG).  
 Within a column, superscripts not containing the same letter denote a significant 
difference between associated parameter means (P < 0.05).  †Pharmacokinetic values for Calf 
#31 in the PRG group which are extremes. 
 
Parameter Group Mean SD Minimum Median Maximum 
              
AUC PRF 87.0 46.2 49.0 74.2 178 
(h*µg/mL) PRG 149.0 79.0 38.8† 186.0 220 
 RG 86.2 26.4 53.6 85.4 129 
  
     Cl/F PRF 6.80 2.16 3.65 7.29     9.74 
(mL/h/kg) PRG 5.34 4.56 2.31 2.74 13.40† 
 RG 6.44 1.89 4.01 6.30    9.37 
  
     K01 PRF 0.2370a 0.0478 0.1770 0.2370 0.294 
(h-1) PRG 0.1530ab 0.1280 0.0449 0.0898 0.341 
 RG 0.0815b 0.0188 0.0525 0.0792 0.104 
  
     K10 PRF 0.0188 0.0059 0.0112 0.0211 0.0253 
(h-1) PRG 0.0310 0.0275 0.0119 0.0219 0.0858† 
 RG 0.0289 0.0064 0.0213 0.0285 0.0373 
  
     V/F PRF 365a 57 295 353 438 
(mL/kg) PRG 177b 63 106 174 283 
 RG 232b 83 130 235 322 
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Table 4.3.  Selected pharmacokinetic parameters from two published studies in which 
meloxicam was administered orally to cattle. 
 In Study 1, calves were 4-6 month old black and white Holstein calves which received 
meloxicam IV and PO (gavage) in randomized order. In Study 2, calves were 6-8 month old 
calves of mixed breed origin which were dosed orally via gavage concomitantly with 15mg/kg, 
PO gabapentin. 
 
Study 
Parameter 
(Units) 
Dose 
(mg/kg) Route Mean SD Minimum Median Maximum 
1 Cl (mL/h/kg) 0.5 IV 6.1 0.4 4.8 6.0 7.2 
1 Cl/F (mL/h/kg) 1.0 PO 6.4 0.6 3.6 6.6 7.8 
2 Cl/F (mL/h/kg) 0.5 PO 6.0 1.2 4.2 6.0 7.1 
 
 
       1 t½ λz (h) 0.5 IV 20.4 0.7 17.8 20.6 22.8 
1 t½ λz (h) 1.0 PO 28.6 3.6 20 26.3 43.3 
2 t½ λz (h) 0.5 PO 20.5 9.2 8.4 17.6 33.2 
 
  
       1 Vz (mL/kg) 0.5 IV 102 6 80 100 120 
1 Vz/F (mL/kg) 1.0 PO 246 20 202 234 321 
2 Vz/F (mL/kg) 0.5 PO 160 40 87 156 218 
 
                  
 1. Coetzee et al., 2009.   
 2. Coetzee et al., 2010.   
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Chapter 5 - Effect of oral meloxicam on performance and health of 
stocker calves after castration4 
 
 Introduction 
 In the beef cattle industry, at weaning time, calves generally undergo a period of extreme 
stress in which they are weaned from their dams, transported for various distances, commingled 
with other calves at either the livestock market or feedlot facility, and undergo a change in 
feeding practice.  The immune system is negatively affected by such stressors, which makes the 
animal more susceptible to contracting infectious agents and succumbing to disease at a time 
when commingled with calves of different backgrounds.  Bovine respiratory disease (BRD), with 
multiple causative bacterial and viral organisms, is the most common cause of illness and death 
in feedlot calves, with the highest incidence of disease occurring within 28 days of arrival at the 
feedyard (Buhman et al., 2000; Duff and Galyean, 2007).  The disease is costly in terms of 
animal welfare, feedlot performance, carcass quality, medicines, time, and manpower.  In 
comparison to calves not treated for BRD, it has been reported that the profit (carcass value - 
total feedlot costs, in year 2001 dollars) is $40.64 less for calves treated once for BRD, $58.35 
less for calves treated twice, and $291.93 less for calves requiring three treatments (Fulton et al., 
2002). 
Bull calves may be castrated before weaning, but many are not castrated until reaching 
the feedlot, further stressing the animal.  The surgical castration of cattle is generally followed by 
a period of decreased animal performance as evidenced by reduced average daily gain (ADG), 
daily feed intake (DFI), and gain-to-feed ratio (ADG:DFI), (Faulkner et al., 1992; Bretschneider, 
2005; Stafford and Mellor, 2005; AVMA, 2011; Massey et al., 2011).  Furthermore, surgical 
castration is associated with increased levels of cortisol and acute phase proteins such as 
                                                 
4Data republished with permission from “Effect of oral meloxicam on health and performance of beef steers relative 
to bulls castrated on arrival at the feedlot” by J.F. Coetzee, L.N. Edwards, R.A. Mosher, N.M. Bello, A.M., 
O’Connor, B. Wang, B. KuKanich, D. A. Blasi. 2012. Journal of Animal Science.  90:1026-1039. American Society 
of Animal Science. 
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haptoglobin, with ensuing immune suppression which may increase the likelihood of the animal 
succumbing to disease. (Fisher et al., 1997; Earley and Crowe, 2002).  
Studies have reported beneficial health and performance effects from administering a 
non-steroidal anti-inflammatory drug (NSAID) in the peri-castration period (Fisher et al., 1997; 
Earley and Crowe, 2002; Baldridge et al., 2011).  In those studies, the drugs were delivered in 
either the drinking water (sodium salicylate) or by intravenous injection (ketoprofen).  Recent 
studies indicate that orally-dosed generic meloxicam, with a plasma half-life of approximately 24 
h, may be a relatively inexpensive and easily-administered alternative for delivering NSAID 
medication in a feedlot setting (Coetzee et al. 2009, 2010).  The objective of this study was to 
investigate the effect of oral meloxicam on performance and health of bull calves following 
surgical castration. 
 Materials and Methods 
This study was approved by the Institutional Animal Care and Use Committee at Kansas 
State University (KSU).  
The study was a stratified parallel design, with calves placed in one of two strata 
depending upon the time of castration.  Calves in the STR strata were castrated prior to arrival to 
at the study facility, with no evidence of scrotal inflammation or scab.  Calves in the XBL strata 
were received as bulls and then castrated approximately 24h following arrival. The drug 
treatment factor consisted of two levels: 1) meloxicam, 1 mg/kg bodyweight administered orally 
on arrival (MEL) and 2) a lactose powder placebo (CONT) administered similarly. Thus, the two 
strata and treatment combinations were: steers to be sham castrated and receive a placebo (STR-
CONT); steers to be sham castrated and receive meloxicam (STR-MEL);  bulls to be surgically 
castrated and receive a placebo (XBL-CONT); and bulls to be surgically castrated and receive 
meloxicam (XBL-MEL). 
 Animals and housing 
Over a 2 week period in March 2010, two hundred fifty-eight crossbred beef calves, (145 
bulls and 113 steers) were obtained from Tennessee livestock commission barns and, in three 
loads of 83 to 88 calves each, transported approximately 1100 km to the KSU Beef Stocker Unit 
where the study was conducted.  One truckload (Lot) of calves was processed per day, with at 
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least three days intervening between each load. The calves were approximately 6 to 8 months 
old, with a mean weight ± SD and range of, 246 ±16 kg, 194 – 285 kg.   
Upon arrival, calves were weighed and identified with numeric ear tags.  An ear notch 
tissue sample was collected for bovine viral diarrhea (BVD) analysis by antigen capture ELISA, 
and all calves were subsequently confirmed negative for BVD virus.  Scrotal palpation was 
performed to determine if calves were to be placed in either the XBL or STR stratum.  Only 
steers with well-healed scrota and no scrotal inflammation were enrolled in the study. Using a 
previously-prepared assignment sheet (one for each strata) constructed by assigning random 
numbers to each block of two animals of the same gender status, calves were assigned to either 
the MEL or CONT group and dosed immediately thereafter.  To calves in the MEL group, 
meloxicam tablets (Meloxicam Tablets USP 15 mg (NDC 29300-125-01), Unichem 
Pharmaceuticals (USA) Inc. Rochelle Park, NJ; Lot # GMMH09021) were administered orally 
with a target dose of 1 mg meloxicam/kg bodyweight. The dose was rounded down to the nearest 
whole tablet, pulverized with mortar and pestle, suspended with tap water in a 60 ml dosing 
syringe, then administered into the oropharynx of the calf.   Calves in the CONT group were 
similarly dosed, substituting in place of meloxicam, an equivalent volume of D(+) lactose 
monohydrate powder (Fluka Analytical, Buchs, Germany) which is a pharmacologically inert 
carrier used in the manufacture of meloxicam tablets.  KSU Stocker Unit personnel were blinded 
to the MEL and CONT treatments. 
After processing and dosing, the truckload of calves was housed overnight in 6 holding 
pens where they were given prairie hay and water.  On d 1, approximately 24 h after the dosing, 
calves were returned to the chute area for further processing and the administration of the 
castration treatment.  Blood samples were collected from the jugular vein of all calves into 
heparin tubes for determination of plasma meloxicam levels. Calves were vaccinated with a 
commercial modified-live, viral respiratory vaccine containing infectious bovine rhinotracheitis 
virus, parinfluenzavirus-3, bovine viral diarrhea virus, bovine respiratory syncytial virus and 
Mannheimia haemolytica (Pyramid 5+ Presponse SQ, Fort Dodge Animal Health, Wyeth, 
Madison, NJ), a multivalent clostridial vaccine (Calvary 9, Intervet/Schering-Plough Animal 
Health, Boxmeer, Netherlands), injectable ivermectin (Ivomec, Merial Limited, Duluth, GA) and 
a metaphylactic antimicrobial, ceftiofur crystalline free acid (Excede, Pfizer Animal Health, New 
York, NY).  
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Castration was performed by the same experienced person using an open surgical 
technique.  Briefly, the scrotum of each calf was cleaned with dilute chlorohexidine disinfectant 
and split twice vertically with a Newberry knife (Jorgensen Lab, Loveland, CO). The testes and 
spermatic cords were exteriorized by blunt dissection and manual traction. The spermatic cords 
were cut using a White’s Double Crush emasculator (Jorgensen Lab, Loveland, CO) applied for 
approximately 30 s. The scrota of steers were cleaned and handled, but no incision was made. 
Calves were then diverted into their assigned pens, which had been determined by 
creating two blocks per truckload based upon the previous day’s receiving weight.  Through 
random number assignment, calves in each block were assigned to one of two pens per 
treatment.  In the feedlot, pens were blocked in groups of four, with treatments assigned 
sequentially in the following order: XBL-CONT, STR-CONT, XBL-MEL, and STR-MEL.  
After all 3 truckloads were received and processed, there were 6 pens of each treatment. Groups 
of 14 or fewer calves, all treated alike, were housed in open, dirt pens measuring 192 m2 with 12 
m of bunk space and one water source. The stocking density (mean ± SD and range) of XBL 
calves was 12 ± 1 (10 to 14), and of STR calves was 9 ± 1 (8 to 11); and was balanced between 
MEL and CONT treatments within the strata.   
 On d 14, calves were reweighed and revaccinated with the viral respiratory vaccine 
(Pyramid 5+ Presponse SQ, Fort Dodge Animal Health, Wyeth, Madison, NJ) and given an 
application of pour-on eprinomectin (Eprinex, Merial Limited, Duluth, GA). On d 28, calves 
were weighed for the final time at the end of the study. 
 
Feeding program   
On arrival, calves were provided a diet consisting of prairie hay containing 7.0% crude 
protein and 0.44 mcal/kg NEg and ad libitum water. Beginning 2 days after arrival, in the 
percentages outlined on Table 1, the calves were fed a total mixed ration (TMR) consisting of 
prairie hay, alfalfa hay, dry rolled corn, wet corn gluten feed, and a commercial premix pellet 
(Cargill Animal Nutrition, Minneapolis, MN). This ration was formulated to contain 15.2% 
crude protein and 1.09 mcal/kg NEg. Beginning 8 days after arrival and continuing through day 
18, calves were fed a TMR incorporating the same ingredients as above, but containing 15.2% 
crude protein and 1.14 mcal/kg NEg. On day 19 and continuing through the study endpoint, 
calves were fed a TMR utilizing the same ingredients formulated to contain 14.4% crude protein 
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and 1.20 mcal/kg NEg.  Daily feed allowances to each pen were recorded along with the weight 
of unconsumed feed to arrive at daily pen intake. 
 
Health program  
Twice daily, personnel at the KSU Beef Stocker Unit evaluated the general appearance 
and attitude of the cattle. If a calf appeared unthrifty as gauged by posture and behavior, it was 
brought to the processing area to complete the health evaluation and obtain a rectal temperature 
and to determine if the animal met the criteria for inclusion in the study as a BRD event.  For 
diagnosis as a BRD event, cattle must have registered a rectal temperature of >103.6ºF (39.8°C) 
and met a minimum visual depression score of 2 as described on Table 2, without symptoms 
attributable to bodily injury or disease unrelated to the respiratory system. 
Calves with visual signs of BRD and a temperature of <103.6ºF were not treated initially, but if 
signs were present for two consecutive days, calves were treated with an antimicrobial regardless 
of temperature. All calves diagnosed with BRD were treated with a single dose of 12.5 mg/kg SC 
enrofloxacin (Baytril, Bayer Animal Health, Shawnee Mission, KS). After 72 h post-treatment, if 
the calf’s temperature was >103.6ºF (39.78°C), it was treated secondarily with 40 mg/kg 
florfenicol SC (Nuflor, Intervet/Schering-Plough Animal Health, Boxmeer, Netherlands). If the 
temperature was calf  >103.6°F (39.78°C), after another 72 h, it was treated with 22 mg/kg 
oxytetracycline (Biomycin 200, Boehringer Ingelheim Vetmedica, Inc, St Joseph, Mo.). After 
treatments, cattle were returned to their home pen. Animal health data recorded for each calf 
identified as sick included the pull date, the individual animal identification number, body 
temperature, clinical score, a presumptive diagnosis, bodyweight and treatment. 
Other health conditions that were monitored and included in calculation of overall 
morbidity included lameness, scrotal infection, and coccidiosis.  Diagnosis of lameness was 
based on signs of persistent limping and reduced weight bearing on one or more limb during 
standing and walking. A diagnosis of scrotal infection was based on signs of depression, fever 
and the presence of swelling and purulent discharge from the castration site. A diagnosis of 
coccidiosis was based on signs of diarrhea, anorexia and depression and the presence of coccidia 
oocysts on microscopic examination of the feces.  
Animals were removed from the study only if a significant illness or injury that 
compromised the welfare of the animal occurred.  All calves that became severely injured or 
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moribund were humanely euthanized. Animals that died or were euthanized during the study 
were transferred to the KSU Veterinary Diagnostic Laboratory for necropsy and disposal. 
 
Calculation of response variables  
Average daily gain (ADG), days on feed (DOF), and daily dry matter intake (DMI) were 
calculated for all animals that completed the 28-day study. All calculations, based upon (Hannon 
et al., 2009) were as follows: 
 
 
 
 
 
 
 
 
 
 
 Plasma meloxicam analysis   
102 
 
Although blood samples were obtained from all calves for consistency of treatment, only 
samples from calves in the MEL group were assayed for meloxicam concentration.  Blood 
samples collected on d 1 were centrifuged for 10 min at 1,500 g, plasma was then harvested, then 
placed in cryovials, and held at –70o C until analysis. All samples were analyzed within 60 days 
after sample collection. 
Plasma concentrations of meloxicam (mass:charge ratio [m/z] 352.09→114.90) were 
determined with high-pressure liquid chromatography (Shimadzu Prominence, Shimadzu 
Scientific Instruments, Columbia, MD) and mass spectrometry (API 2000, Applied Biosystems, 
Foster City, CA). Plasma samples or standards (100 μl) were added to 100 μl of internal standard 
(piroxicam 0.5 μg/ml in methanol, m/z 332.12→95.10) and 300 μl of methanol with 0.1% formic 
acid to precipitate the proteins. The samples were vortexed for 5 seconds and centrifuged for 10 
minutes at 10,000 ×g. The supernatant, 200 μl, was transferred to an injection vial with the 
injection volume set to 10 μl. The mobile phase consisted of A: acetonitrile and B: 0.1% formic 
acid at a flow rate of 0.4 ml/min. The mobile phase consisted of 85% B from 0 to 0.5 minutes 
with a linear gradient to 50% B at 2.5 minutes, which was maintained until 3 minutes, followed 
by a linear gradient to 85% B at 4 minutes, with a total run time of 5 minutes. Separation was 
achieved with a C8 column (Supelco Discovery C8, 50 mm × 2.1 mm × 5 μm; Sigma-Aldrich, 
St. Louis, MO) maintained at 40°C. The standard curve was linear from 0.01 to 10 μg/ml and 
was accepted if the correlation coefficient exceeded 0.99 and predicted values were within 15% 
of the actual values. The accuracy of the assay was 103% ± 7% of the actual value, and the 
coefficient of variation was 7%, determined on replicates of 5 each at 0.025, 0.5, and 5 μg/ml.  
 Statistics  
When all calves were received, enrolled, and randomized, the treatment groups and 
number of animals in each were: XBL-CONT (n=74), XBL-MEL (n=71), STR-CONT (n=55), 
and STR-MEL (n=58). 
Health, performance, and plasma meloxicam data were analyzed using generalized linear 
mixed models fitted with the GLIMMIX procedure of SAS Version 9.2 (SAS Institute, Cary, 
NC). Performance outcomes (DMI, ADG, G:F ratio) and meloxicam concentrations were 
modeled as Gaussian using an identity link function. The frequency of health events (Pull, 
morbidity, BRD) in a given pen were modeled using a binomial distribution whereby the number 
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of binomial trials was defined by number of animals in a pen. The logit link function was used to 
model health events. Pen served as the experimental unit for all outcomes. Least square mean 
estimates for each treatment group and the corresponding estimated SE are reported. Pairwise 
comparisons were conducted using Bonferroni's method to adjust for multiple comparisons and 
avoid inflation of Type I error rate. Statistical significance for these multiple comparisons was 
designated a priori as a P-value ≤ 0.05. 
For the statistical models on performance outcomes, the linear predictor included the 
fixed effects of stratum (XBL or STR), drug treatment (MEL or CONT), time (d 14 and d 28), 
and all 2- and 3-way interactions. Included in the model were the random blocking effect of Lot 
and the random effect of Pen to recognize the experimental unit for treatment groups. Repeated 
observations within a pen were modeled using a compound symmetry residual variance-
covariance structure. For DMI, the residual variance-covariance was expanded to accommodate 
heterogeneous variances at each time period. In turn, for meloxicam concentrations measured 24 
h after drug administration, the linear predictor included the fixed effect of stratum (XBL, STR) 
and the random blocking factor of Lot. For all models fitted on Gaussian responses, Satterthwaite 
method was used to estimate degrees of freedom and Kenward Rogers was used for bias 
correction in standard error estimation. Newton-Raphson with ridging was the estimation 
algorithm implemented. Model assumptions were evaluated using externally studentized 
residuals and were considered to be appropriately met. For health events at each period of 
observation, the linear predictor for the statistical model included the fixed effects of stratum 
(XBL or STR), drug treatment (MEL or CONT), and their 2-way interaction. Entry BW did not 
enhance model fit and thus, was excluded from the final model. The random effect of Lot was 
also fit in the linear predictor as a blocking factor to account for variability in health events 
between lots. In addition, Pen nested within stratum and drug treatment was incorporated in the 
linear predictor to recognize Pen as the experimental unit for these factors. For binomial 
responses, inference was conducted after checking for absence of overdispersion based on the 
Pearson Chi-Square/degrees of freedom fit statistic. Model parameters were estimated using 
Laplace integral approximation to maximum likelihood. 
Least squares means (SEM) and mean differences (SED) are reported unless specifically 
identified as a mean ± SD for descriptive statistics such as receiving weight of calves. 
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 Results 
Eight calves were removed from the study prior to completion as shown on Table 3.  One 
calf was found dead in the pen due to diffuse necrotizing phlebitis of the external iliac and 
femoral veins with associated thrombo-embolic pneumonia.  Including only the calves which 
completed the study, the mean receiving weight ± SD of the treatment groups was: STR-CONT 
(245 ± 15 kg), STR-MEL (245 ± 16 kg), XBL-CONT (248 ± 16 kg), XBL-MEL (247 ± 17). 
 Meloxicam concentrations 
Due to handling error, plasma samples were not available for meloxicam assay for 3 
XBL-MEL and 2 STR-MEL calves.  Dividing the actual dose administered by the receiving 
weight of the calf, the dose of meloxicam rounded down to the nearest whole tablet ranged from 
0.89 – 1.00 mg/kg. There was no difference (P = 0.70) in mean ± SEM plasma meloxicam 
concentrations at the time of castration, between XBL (6.01 ± 0.07 μg/mL) and STR (5.97 ± 0.7 
μg/mL) groups.   
 Performance  
 Meloxicam administration did not affect the ADG, DMI, or the ADG:DMI ratio of 
calves: there was no evidence (P > 0.3) of a main effect nor any interaction with strata and/or 
days on feed (Table 4).  
Dry matter intake was significantly affected by strata (P = 0.016) and DOF (P < 0.001), 
but there was no interaction between those fixed effects as shown on Figure 2a.  Over the course 
of the 28-day study, DMI of calves in the STR stratum was 0.37 ± 0.13 kg/d higher (P = 0.02) 
than those in the XBL stratum. For all calves, dry matter intake was 2.19 kg/d higher in the 15- 
28 d period than in the 1 – 14 d period (P < 0.001).    
With regard to ADG and the ADG:DMI ratio, as shown on Figure 2b and c, there was an 
interaction between strata and DOF (P ≤ 0.002), with the STR group having a higher ADG 
(difference, 0.75 ± 0.14 kg/d; P < 0.0001 ) and ADG:DMI ratio (difference, 0.13 ± 0.02; P < 
0.0001) than the XBL group from 1 to 14 DOF, but no difference  between strata from 15 to 28 
DOF (P ≤ 0.31).   
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 Health 
 The various pull rates, overall morbidity, and the incidence of BRD are listed in Table 5a 
and 5b and depicted in Figure 3.  The rate at which XBL calves were pulled for further health 
evaluation was significantly higher than STR calves (P = 0.01).  Within the STR stratum, there 
was no difference (P = 0.78) between the pull rate of calves which received meloxicam (17%) 
and those which did not (20%). Within the XBL stratum, however, the pull rate of calves which 
received meloxicam (26%) was significantly lower (P = 0.04) than those which did not (45%).  
Within the placebo treatment, the pull rate of XBL calves (46%) was higher (P = 0.007) than 
STR calves (20%); but within the meloxicam treatment, there was no difference (P = 0.43) 
between XBL (26%) and STR (17%) calves. 
 The highest daily detection of BRD cases peaked within the first 14 days of the study 
(Figure 4).  Over the entire 28-day study, with respect to the incidence of BRD, there was no 
evidence (P = 0.31) to indicate a main effect of drug treatment, but there was marginal evidence 
(P = 0.06) of an effect of stratum. Comparing within stratum, there was a significantly (P = 0.03) 
higher incidence of BRD in castrated calves which received the placebo (34%) than those which 
received meloxicam (17%), whereas within the STR stratum, there was no difference (P = 0.67) 
in BRD incidence between calves receiving either drug treatment.  
 As shown in Table 5a and 5b, there were no differences between strata or treatment 
groups for the first and second re-pull rates and their associated rates of BRD relapse. 
 Discussion 
This study investigated the effect of administering oral meloxicam at a dose of 1 mg/kg 
to transportation-stressed beef calves immediately upon arrival to the feedlot, followed by 
castration of bulls 24 h later.  Steer calves, with a sham castration, were used as controls for the 
castration procedure. 
The mean plasma concentration of meloxicam in this study was approximately 6 µg/mL 
24 h after administration.  In pharmacokinetic studies with calves, when meloxicam was 
administered orally at doses of 1 mg/kg (Coetzee et al., 2009) and 0.5 mg/kg (Coetzee, et al. 
2010) the mean peak plasma concentrations were reached in approximately 12 h with values of 
3.1 µg/mL (dose, 1 mg/kg) and  2.1 µg/mL (dose, 0.05 mg/kg).  Although it is not possible to 
calculate the maximum plasma concentration from the one sample collected in the current study, 
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it is likely that peak concentrations ranged between 2 and 3 times that observed in Coetzee, et al. 
2009 with a similar dose.  The reason for the higher concentrations observed in the current study 
is not known.  But in previous studies, food and water were not withheld prior to dosing, whereas 
in the current study, calves did not have access to food and water for at least 12 h prior to dosing.  
A lower volume of rumen contents may have resulted in less opportunity for the drug to bind to 
ingesta, and when the calves drank water following release into their pens, a  greater portion of 
the dose would likely have been free  to wash out of rumen and travel to the small intestine for 
absorption than if the rumen had been full.  To test this hypothesis, it would be necessary to 
perform a pharmacokinetic study with oral meloxicam being administered to calves when food 
and water are withheld for approximately 12 h prior to dosing. 
Castration significantly reduced the ADG, DMI, and ADG:DMI of calves during the first 
two weeks following the procedure.  Reduced gains and feed efficiency in castrated calves was 
expected since surgical castration is generally followed by a period of reduced weight gain, the 
severity of which is usually directly related to the age of the animal at the time of the procedure. 
(Faulkner et al., 1992; Bretschneider, 2005; Stafford and Mellor, 2005; AVMA, 2011; Massey et 
al., 2011).  Even though gains and feed intake in the ensuing weeks may be similar between 
castrated and non-castrated calves, as observed in our study, cumulative ADG may be reduced 
through 27 to 35 days. (Cohen et al., 1991; Fisher et al., 1996).  ADG values were higher in this 
study than in some others; this is likely the result of using the artificially low receiving weight as 
the beginning weight, whereas the ending weights were obtained without restriction of food and 
water.   
The administration of meloxicam did not improve the ADG, DMI or ADG:DMI of 
castrated calves in this study.    Performance effects of NSAID administration upon castration 
have been mixed.  Administration of the NSAID ketoprofen at various dosage regimens in the 
peri-surgical period did not prevent the reduced ADG in 11-mo-old castrated calves in the 1-35 
day period. (Ting et al. 2003).  Earley and Crowe (2002), however, reported that 5.5-month-old-
calves receiving ketoprofen combined with local anesthesia prior to surgical castration had a 
higher ADG during the 35 days after castration compared with untreated calves. Baldridge et al. 
(2010) found that 2- to 4-month-old calves receiving the NSAID sodium salicylate in drinking 
water beginning 3 d prior to concurrent surgical castration and dehorning and continuing for 2 d 
after surgery had a higher ADG over 13 days after the procedure than untreated calves.  It is 
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possible that NSAID administration is more effective in maintaining ADG in younger calves, 
though more evidence is needed to support this hypothesis. 
The most noteworthy finding of the current study was that the administration of 
meloxicam significantly reduced the percentage of castrated calves which were diagnosed with 
BRD.  Within the XBL strata, calves castrated after administration of the placebo were twice as 
likely to be treated for BRD as those castrated after administration of meloxicam.  The incidence 
of BRD in the castrated calves which received meloxicam was reduced to that of the steers.  
Within the STR strata, the administration of meloxicam had no effect on the rate of BRD.  
The finding of increased risk of developing BRD in castrated calves was expected.  In a 
multi-year study of 3,380 stocker calves (65% bulls, 35% steers) similarly shipped from sources 
in Tennessee and Kentucky to the KSU Stocker Unit, Massey et al (2011) reported that calves 
which were surgically castrated 24 h post-arrival were treated for BRD significantly more often 
than calves which were received as steers. Similar observations have been reported by others 
(Daniels et al., 2000; Pinchak et al., 2004).  Additionally, Pinchak et al. (2004) reported marginal 
evidence of decreased ADG in calves with BRD. 
The mechanism by which castrated calves may be more susceptible to developing BRD is 
thought to be due to immunosuppression resulting from stress and surgery.  Surgical castration is 
associated with increased plasma concentrations of cortisol and acute phase proteins such as 
haptoglobin (Fisher et al., 1997; Earley and Crowe, 2002).  Acute phase proteins have been 
shown to suppress lymphocyte function in cattle and may act as a negative feedback mechanism 
to inhibit further inflammation (Murata, 2003).   Ting et al., (2003) and Earley and Crowe (2002) 
demonstrated that administration of the NSAID, ketoprofen, to surgically castrated calves 
decreased the concentrations of circulating cortisol and haptoglobin, and also prevented 
suppression of the gamma-interferon response. Although concentrations of cortisol, haptoglobin, 
or gamma-interferon were not measured in the current study, the findings of Ting et al (2003) 
and Early and Crowe (2002) suggest the mechanism whereby meloxicam administration may 
have may limited the immunosuppression usually associated with surgical castration, thus fewer 
XBL-MEL calves succumbed to BRD than XBL-CONT calves. 
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that is a potential 
candidate for use in providing pain relief to cattle.  As a class, NSAIDs exert anti-inflammatory 
action through variable inhibition of the cyclo-oxygenase (COX) isoenzymes which are pivotal 
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catalysts in the prostaglandin production pathway.  While the expression of both COX-1 and 
COX-2 is constitutive and inducible, COX-2 is the isoform which is greatly upregulated in the 
presence of inflammatory stimuli and is therefore considered to be the desired target of NSAID 
activity (Lees, 2009).  Although the literature is deficient with respect to cattle, meloxicam is 
considered to preferentially inhibit the inflammatory effects of COX-2 while tending to spare the 
homeostatic effects of COX-1 in humans (Warner et al., 1999), dogs (Streppa et al., 2002), cats 
(Giraudel, et al., 2005), and horses (Beretta, et al., 2005). However, the relative inhibition of the 
COX isoenzymes by a drug is known to vary between species, therefore COX preference in one 
species does not guarantee similar preference in another (Lees, 2009). 
Although meloxicam is not currently approved for use in cattle in the United States, the 
drug has been approved for that use in in the European Union as well as in countries such as 
Canada, New Zealand, and Australia, which are major suppliers of beef products to the U.S 
(USDA, 2009).  Depending upon the country, approved indications variously include the use of 
meloxicam as ancillary treatment of respiratory disease, diarrhea, mastitis and/or pain due to 
dehorning or disbudding.  Based on a dose of 0.5 mg/kg bodyweight delivered intravenously or 
subcutaneously, labeled withdrawal times range from 8 to 20 days for meat, and from 84 hours to 
6 days for milk (EMEA, 1999; APVMA, 2010; NZFAZ, 2010; Health Canada, 2009). 
In the U.S., although flunixin meglumine is approved for the control of pyrexia associated with 
bovine respiratory disease and for the control of inflammation and pyrexia associated with 
endotoxemia (FDA, 2003), there is currently no approved NSAID with indications for alleviating 
pain in cattle.  Provisions in the Animal Medicinal Drug Use Clarification Act of 1994 may 
therefore allow the extra-label use of meloxicam under specific conditions as discussed 
previously (Coetzee et al., 2009).  Candidate products for extra-label use in cattle include oral 
and injectable small animal formulations, and oral human formulations.   
As determined by a study investigating the pharmacokinetics of generic human-label 
meloxicam when dosed orally to ruminant calves at 1mg/kg BW, the drug was observed to be 
well absorbed, with a mean bioavailability of 100% and a plasma elimination half-life of 27 h 
(Coetzee et al., 2009).  With the long half-life and the relative ease of oral dosing,  meloxicam 
may provide producers with an affordable and effective route for providing pain relief and to 
possibly enhance animal well-being in the weeks following transport and subsequent castration 
in a feedlot receiving environment.  The generic human product used in the current study was 
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available commercially to veterinarians at a price of $0.0033/mg, which translates to an 
approximate base cost of $0.83 per 250 kg calf.  Even after adding a margin for profit, the cost 
compares favorably to the estimated $40.64 loss due to BRD treatment (Fulton et al., 2002). 
 Conclusion  
The administration of meloxicam to calves in this study did not improve ADG, DFI, or 
ADG:DFI in either XBL or STR calves.  Under the conditions and limitations of this pilot study, 
the oral administration of meloxicam, 24 h prior to surgical castration, significantly reduced the 
incidence of BRD diagnosis in castrated bull calves in the 28 d post-surgical period.   
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 Figures and Tables  
 
Figure 5.1.   Study outline representing timeline for calves administered lactose placebo 
(CONT) or meloxicam (MEL; 1 mg/kg, oral) 24 h prior to either surgical castration of bulls 
(XBL) or sham castration of steers (STR).  
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Figure 5.2.  a) Dry matter intake (DMI), b) Average daily gain (ADG), and c) ADG:DMI 
ratio in calves administered lactose placebo (CONT) or meloxicam (MEL; 1 mg/kg, oral) 
24 h prior to either surgical castration of bulls (XBL) or sham castration of steers (STR). 
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Figure 5.3.  Overall rate of first pull for examination, incidence of disease for all causes, 
and incidence of bovine respiratory disease (BRD) in calves administered lactose placebo 
(CONT) or meloxicam (MEL; 1 mg/kg, oral) 24 h prior to either surgical castration of bulls 
(XBL) or sham castration of steers (STR).  
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Figure 5.4.  Daily incidence of bovine respiratory disease (BRD) detections in calves 
administered lactose placebo (CONT) or meloxicam (MEL; 1 mg/kg, oral) 24 h prior either 
surgical castration of bulls (XBL) or sham castration of steers (STR).  
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Table 5.1.  Percentages of dietary components in the total mixed ration, as fed to calves. 
 
 
 
 
 
 
 
 
 
1Contains 600 g/ton monensin 
2Sweetbran, Cargill Animal Nutrition, Minneapolis, MN 
Days on feed 1 to 7 8 to 18 19 to 28 
     
Supplement1, %    3   3   3 
Dry-rolled corn, %  28 29 36 
Wet gluten feed2, %  30 37 37 
Prairie hay, %  16 16 15 
Alfalfa hay, %  23 15 9 
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Table 5.2.  Depression scoring system used to determine sickness and diagnose Bovine 
Respiratory Disease (BRD) in calves (adapted from Perino and Apley, 1998) 
 
Depression 
Score 
Clinical Signs  
0 Normal, no signs of depression  
1 Noticeable depression without signs of weakness. Slower than pen mates but 
perks up when approached, raises head and actively follows observer’s 
movements.  
2 Marked depression with moderate signs of weakness, but without a 
significantly altered gait. Stands with head lowered, perks up when 
approached but soon returns to depressed stance. Moves slower than pen 
mates, may display signs of incoordination  
3 Severe depression with signs of severe weakness such as a significantly 
altered gait. Stands with head lowered and raises head only when approached 
closely. Not easily able to stay with pen mates. 
4 Moribund, unable to rise  
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Table 5.3.  Enrollment and health statistics in long-haul transported calves, receiving either placebo (CONT ) or meloxicam,1 
mg/kg administered orally upon arrival (MEL). Approximately 24 h after arrival, bull calves (XBL) were surgically castrated 
and steers (STR) were sham-castrated.    
 
  Treatment Group  
  Bulls (XBL) Steers (STR) 
  XBL-CONT XBL-MEL STR-CONT STR-MEL 
Calves enrolled in study 74 71 55 58 
Calves completing study 73 67 53 57 
Removed from study 1  4 2   1 
     Reason for removal:         
       Lameness 1  2  1  1 
      Chronic coccidiosis 0 1  0 0 
      Neurological signs 0 1  0 0 
      Pen Death 0 0 1  0 
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Table 5.4.  Least squares means of average daily weight gain (ADG), daily dry matter intake (DMI) and gain-to-feed ratio 
(ADG:DMI) in long-haul transported calves, receiving upon arrival the treatment (Trt) of either placebo (CONT ) or 
meloxicam, 1 mg/kg administered orally (MEL).   
Approximately 24 h after arrival, calves in the bull stratum (XBL) were surgically castrated and calves in the steer stratum 
(STR) were sham-castrated.    
 
    P-values 
St
ra
ta
*T
rt*
D
O
F Strata XBL STR   
St
ra
ta
 
Tr
t 
D
O
F 
St
ra
ta
*T
rt 
St
ra
ta
*D
O
F 
Tr
t*
D
O
F Trt
 Placebo Meloxicam Placebo Meloxicam SEM 
DOF1 1 - 14 15 – 28 1 – 14 15 – 28 1 - 14 15 – 28 1 - 14 15 – 28 1 - 14 15 – 28 
ADG, kg 0.78 1.54 0.95 1.5 1.72 1.37 1.51 1.46 0.18 0.18 <0.001 0.97 0.08 0.30 0.002 0.85 0.31 
DMI, kg 4.70 6.95 4.80 7.01 5.26 7.39 5.06 7.23 0.22 0.31 0.016 0.73 <0.001 0.35 0.73 0.98 0.85 
ADG:DMI,% 0.16 0.22 0.19 0.21 0.32 0.19 0.30 0.20 0.03 0.03 <0.001 0.73 0.07 0.34 <0.001 0.95 0.33 
 
1DOF: Days on Feed. ADG: Average Daily Gain. DMI: Daily Dry Matter Intake  
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Table 5.5  Least squares means of health monitoring response variables in long-haul transported calves, receiving upon arrival 
the treatment (Trt) of either placebo (CONT) or meloxicam, 1 mg/kg administered orally (MEL).  
Approximately 24 h after arrival, calves in the bull stratum (XBL) were surgically castrated and calves in the steer stratum 
(STR) were sham-castrated.  Contrasts between groups are not shown for the third pull (Table b.) because there were no significant 
differences within Strata or treatment groups. 
Strata XBL STR 
P-values 
P-values of contrasts 
Treatment (Trt) CONT MEL CONT MEL 
XBL-CONT 
v. STR-
CONT 
XBL-MEL 
v. STR-
MEL 
XBL-
CONT 
v. XBL-
MEL 
STR-
CONT 
v. STR-
MEL 
Strata-Treatment combination XBL-CONT XBL-MEL 
STR-
CONT 
STR-
MEL 
Strata Trt Strata*Trt 
First Pull            
     Pulls for all reasons, % 45 (11) 26 (9) 20 (6) 17 (9) 0.01 0.07 0.45 0.007 0.43 0.04 0.78 
     Overall morbidity, % 35 (17) 21 (12) 13 (9) 14 (11) 0.08 0.28 0.36 0.004 0.57 0.13 0.87 
     BRD morbidity, % 34 (15) 17 (11) 10 (6) 13 (10) 0.06 0.31 0.21 0.0006 0.68 0.027 0.67 
Second Pull            
     First re-pull for BRD, % 44 ( 14) 53 (8) 27 (16) 70 (21) 0.99 0.14 0.31     
     First BRD relapse, % 33 (12) 36 (14) 33 (22) 50 (20) 0.70 0.60 0.70     
 
b. 
 Strata Treatment (Trt) P-value 
 XBL STR CONT MEL Strata Trt 
Third Pull       
     Second re-pull for BRD, % 30 (48) 4 (25) 22 (52) 6 (31) 0.64 0.67 
     Second BRD relapse, % 36 (20) 0.0001 (0.02) 0.2 (17.4) 0.04 (3.5) 0.94 0.37 
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Chapter 6 - Future Directions for Research 
For cattle in the U.S. today to receive analgesia beyond the short duration of local 
anesthesia with lidocaine, veterinarians and producers must rely upon extra-label drug 
use (ELDU) because there is no drug approved by the FDA for that specific use in cattle.  
In the absence of such an approved drug, as long as the other provisions for ELDU  in the 
Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994 are met along with 
published regulations in the Code of Federal Regulations (21 CFR Part 530), analgesic 
drugs such as meloxicam could be administered to cattle for the relief of pain. 
One of the provisions in AMDUCA for ELDU is that the prescribing veterinarian 
must establish a substantially extended withdrawal period prior to the marketing of any 
portion of the animal for consumption.  As discussed in Chapter 4, to make this 
estimation for oral meloxicam, veterinarians currently must rely upon estimates of the 
terminal elimination half-life from published pharmacokinetic studies in cattle.   
As long as all conditions for ELDU are met, it is possible for veterinarians to 
administer oral meloxicam to cattle using information published to date.  But for a 
meloxicam product, whether injectable or oral, to be approved by the FDA for marketing 
in the U.S., many future studies are needed. Even if a sponsor does not support and amass 
the data necessary to submit a New Animal Drug Application (NADA), future published 
research will add to the body of knowledge needed to use meloxicam safely and 
effectively in providing pain relief to cattle. Therefore, directions for future research 
should lay the groundwork for either reference by practicing veterinarians or by a drug 
sponsor wishing to replicate or extend the studies under the well-controlled conditions 
required for a NADA. 
The CVM has issued a guidance document for use in designing studies to support 
the approval of NSAID’s for use in animals (CVM 2006).  Furthermore, authors from the 
CVM have recently published regulatory considerations intended to provide researchers 
and industry sponsors with the agency’s current thinking on analgesic drug approval for 
cattle in the U.S. (Smith & Modric, 2013).  These documents, within the context of 
federal regulations concerning NADAs (21 CFR Part 514), provide researchers with the 
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framework necessary to the approval of an NSAID, such as meloxicam.  This chapter will 
discuss future research needed to fill in this framework. 
To be approved by the FDA, a new animal drug must be shown to be safe and to 
be effective for the labeled intended use.  Although for a NADA application for a specific 
product, there are other items to address, such as environmental impact and 
manufacturing considerations, because we are not looking at a specific product, this 
chapter will focus on studies necessary to show safety and efficacy. 
 Effectiveness 
In the Effectiveness section of a NADA, sponsors must provide substantial 
evidence in the form of data from adequate and well-controlled studies which 
demonstrate that the drug has the intended effect when used as indicated on the product 
label. (21 U.S.C. § 360b(d)(1)(E))  Dose characterization is one part of this section and 
provides rationale for the dose, frequency, and duration of administration.  The dose of 
oral meloxicam used in published studies in cattle thus far has been derived from the dose 
of the injectable product approved in other countries.  Although this is a reasonable place 
to start, the dose must be demonstrated to be effective for the proposed indication.  For 
the indication of providing pain relief in the form of an NSAID to calves when dehorned 
and/or castrated, a major difficulty is the lack of a validated model with which to measure 
and assess pain in that species.   
As discussed in Chapter 1, current research has been aimed at evaluating various 
response variables which may provide a reliable and reproducible method of measuring 
the effectiveness of pain relief.  Currently, none of these measures has been validated.  
Because cattle may mask pain behaviors in the presence of humans, and because scoring 
of those behaviors by observers is subjective and time intensive, this type of assessment 
is not likely to be easily validated.  Objective, quantifiable assessments of behavior, such 
the use of accelerometers to measure postural activity are more likely to be useful than 
subjective counts of specific behaviors.  A similar posture-assessing device which has not 
been reported in the literature which might be useful in measuring general attitude is one 
which could be applied to the ear which would monitor ear position. 
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Methods which “ask” the animal to show how much it hurts to put pressure on an 
injured area, such as pressure mats and algometers, are intriguing, however, it is 
important to recognize that animals may still mask the necessary behaviors such as 
limping on the pressure mat or moving the head away from a pressure algometer applied 
to a dehorned area.  Furthermore, in the case of pressure algometers applied to a painful 
area, this measure is not totally objective because the algometer is held in the hand of the 
observer who determines when the animal flinches.  Therefore, more research is 
necessary to refine the methodology by which it is measured how much pressure an 
animal is comfortable with.  For example, the method of measuring pressure applied to 
the dehorned area might be improved by developing an apparatus which is attached to the 
head of a confined animal 
Given the inherent difficulty in assessing pain behaviors in cattle, especially those 
that are not conditioned to the benevolent presence of humans, researchers are 
investigating potential biomarkers which may be more specific to pain and inflammation 
such as substance P.   
Another avenue for research into possible biomarkers is to assess the action of 
meloxicam on suppressing the expression of the COX-2 enzyme following an elective 
surgical procedure. With this approach, the indication would be for the control of 
inflammation following the procedure.  In a study in which an inflammatory response 
was induced in calves by intravenously injecting the endotoxin of Escherichia coli, LPS, 
a single administration of meloxicam reduced the inflammatory mediators prostaglandin 
E2, prostaglandin F2a, thromboxane B2 and malonylodialdehyde compared to controls 
(Bednarek & Kondracki, 2006).  A study measuring these inflammatory mediators at 
various timepoints up to 72 hours following castration or dehorning in calves treated and 
not treated with oral meloxicam would indicate the usefulness of these biomarkers.  Such 
a study could also be performed as a dose titration study, with a range of doses, to 
determine if a lower dose is just as effective or, alternately, if a higher dose is needed to 
suppress the inflammatory response.  Pairing a dose titration study, such as described 
here, with pharmacokinetic data and measurement of other pain-response variables may 
assist in determining the effective drug concentration.  This would be helpful in 
determining the proper timing of drug administration. 
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It is also possible that meloxicam, either oral or injectable, may be developed for 
the indication of preventing bovine respiratory disease in the post-castration period.  
Although the results reported in Chapter 5 are promising, the study should be repeated in 
a field study with a larger number of animals under the conditions of actual use. 
 Safety 
Because cattle are a food animal species produced for human consumption, the definition 
of drug safety is extended to include not only safety for the target animal (cattle), for the 
environment, and for the person administering the drug, but also the safety of food products for 
human consumption  (CVM, 2006b).   
 Oral meloxicam is approved in the U.S. for use in humans, dogs, and cats, therefore much 
is already known about the safety of the drug with respect to people and select laboratory 
animals. This information is helpful to veterinarians in the U.S. who administer meloxicam to 
cattle on an extra-label basis, to governmental officials determining residue tolerance limits, and 
to an industry sponsor needing to amass safety data.   
From public information reported in the approval documentation of the injectable 
meloxicam product in the European Union it can be expected that cattle administered oral 
meloxicam might similarly exhibit the reported occasional mild erosion of the abomasal mucosa 
with no major adverse reactions (EMEA, 1999).  But it is possible that the oral product may not 
be as well-tolerated in the GI tract as the injected product.  Therefore, a safety study should be 
conducted in which cattle are administered oral meloxicam at 0, 1, 3, and 5 times the dose 
established in efficacy studies.  The dose should be administered at least 3 times the proposed 
duration.  In such a study, the animals would be monitored for adverse clinical signs and, at the 
end of the study, animals would be sacrificed for gross and histological pathology (CVM, 2009). 
Similarly, the results of residue depletion studies are reported for the injectable product,  
but because it is possible that orally administered meloxicam is eliminated from the various 
edible tissues differently, food safety studies are needed in  animals of the target consumption 
ages, e.g. for veal and beef.  In such a study, animals are dosed at the highest intended level and 
duration, then a portion of the animals sacrificed at intervals throughout the expected withdrawal 
period, and then drug concentrations are determined from edible tissue samples of muscle, fat, 
liver and kidney to determine elimination half-lives (CVM, 2006b).  Because NSAID toxicities 
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may not be found during the typical Target Animal Safety study in healthy animals as described 
above, the CVM also recommends rigorous monitoring of field efficacy studies for adverse 
reactions (CVM, 2006a). 
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